

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



[Please scan this QR Code to view the Prospectus]

Q-LINE BIOTECH LIMITED

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE")

Our Company was originally incorporated as "POCT Services Private Limited" on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to "Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to "Q-Line Biotech Limited", and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled "History and Corporate Structure" beginning on page 152 of the Prospectus.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012
Tel.: +91 522-2435570, **E-mail:** compliance@qlinebiotech.com ; **Website:** www.qlinebiotech.com
CIN: U74120UP2010PLC042528 ; **Contact Person:** Akhand Pratap Singh, Company Secretary & Compliance Officer

OUR PROMOTERS: SAURABH GARG, AMITA GARG, AYUSH GARG, AJAY KUMAR MAHANTY AND ABHAY AGRAWAL

Our Company has filed the Prospectus dated May 26, 2026 with ROC and thereafter with SEBI and the stock exchange and Equity Shares are proposed to be listed on SME Platform of NSE (NSE Emerge) on May 29, 2026.

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE (NSE EMERGE)."

BRIEF DESCRIPTION OF THE BUSINESS OF THE COMPANY

We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of our Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF UPTO 62,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF Q-LINE BIOTECH LIMITED ("OUR COMPANY" OR "QLBL" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹333 PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ 21,448.48 LAKHS ("PUBLIC ISSUE") OUT OF WHICH 3,13,200 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE FOR CASH, AGGREGATING ₹ 1,074.28 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 59,40,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ 20,374.20 LAKHS IS HEREIN REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.81 % AND 25.46 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

**THE FACE VALUE OF THE EQUITY SHARE IS RS. 10/- AND ISSUE PRICE IS RS. 343/- EACH. THE ISSUE PRICE IS 34.30 TIMES OF THE FACE VALUE OF THE EQUITY SHARE
 ANCHOR INVESTOR ISSUE PRICE: RS. 343/- PER EQUITY SHARE.
 THE ISSUE PRICE IS 34.30 TIMES OF THE FACE VALUE**

BID/ ISSUE PERIOD

ANCHOR INVESTOR BIDDING DATE: WEDNESDAY, MAY 20, 2026

BID/ ISSUE OPENED ON: THURSDAY, MAY 21, 2026

BID/ ISSUE CLOSED ON: MONDAY, MAY 25, 2026

RISKS TO INVESTORS:

- Any disruption, stoppage, slowdown or shutdown in our manufacturing facilities or process or research and development activities could adversely affect our business, financial condition, cash flows and results of operations.
- Any delay, interruption or reduction in the supply of our raw materials, trade goods from our suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of our products and have an adverse effect on our business, financial condition, cash flows and results of operations.
- Our business is dependent on the sale of our products through distributors which also include our group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of our products and could negatively impact our business, results of operations, financial conditions and cash flows.
- We are dependent on certain key suppliers to procure a significant portion of our Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in our operations, which could have an adverse effect on our business, financial condition, results of operations and cash flows.
- We are required to obtain, maintain or renew our statutory and regulatory approvals, licenses, and registrations to operate our business.
- For manufacturing of our machines and reagents, we are dependent on the agreement with the European companies, any failure to renew the agreement or entering into the agreement on the terms which are not favourable for us may impact our business operations, financial condition and cash flows.
- Our erstwhile associate company i.e. POCT Science House Private Limited and our promoters namely Saurabh Garg and Amita Garg have been subject to search and seizure operations by the Income-tax Department and any adverse outcome of these proceedings may adversely affect our financial condition.
- Our operations are concentrated in North India, and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.
- Our Company requires a significant amount of working capital for continuing growth. Our inability to meet our working capital requirements may adversely affect our results of operations.
- We are subject to risks arising from exchange rate fluctuations.
- The BRLMs associated with the Issue have handled 79 Public Issues in the past three years, out of which 8 issues were closed below the Issue Price on listing date:

- Average cost of acquisition of Equity Shares held by the Promoters is

| Sr. No. | Name of Promoter | No. of Shares held | Average Cost of Acquisition (in ₹) |
|---------|--------------------|--------------------|------------------------------------|
| 1. | Saurabh Garg | 1,01,91,000 | 0.04 |
| 2. | Amita Garg | 39,37,480 | 0.00 |
| 3. | Ayush Garg | 31,500 | 0.00 |
| 4. | Ajay Kumar Mahanty | 7,50,000 | 18.34 |
| 5. | Abhay Agrawal | 7,56,010 | 0.00 |

- The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end (₹343) of the Price Band is 11.98
- Weighted Average Return on Net worth for Fiscals 2025, 2024 and 2023 is 23.17%.
- The Weighted average cost of acquisition of all Equity Shares transacted in the last one year, 18 months and three years from the date of Prospectus is as given below:

| Period | Weighted Average Cost of Acquisition (in Rs.) | Cap Price (₹343) is 'X' times the Weighted Average Cost of Acquisition | Range of acquisition price: Lowest Price – Highest Price (in Rs.) |
|---|---|--|---|
| Last one year, Last 18 Months, three years preceding the date of the Prospectus | 17.88 | 19.18 | 0-343 |

- The Weighted average cost of acquisition compared to Floor Price and Cap Price.

| Types of transactions | Weighted average cost of acquisition (₹ per Equity Shares of face value of Rs. 10/-) | Floor price (i.e. ₹ 326) | Cap price (i.e. ₹ 343) |
|---|--|--------------------------|------------------------|
| Weighted average cost of acquisition of primary / new Issue | NA [^] | NA [^] | NA [^] |
| Weighted average cost of acquisition for secondary sale / acquisition | NA ^{^^} | NA ^{^^} | NA ^{^^} |
| Weighted average cost of acquisition of primary issuances/ secondary transactions | 17.89 | 18.22 | 19.17 |

Note:

[^]There were no primary/ new issue of shares (equity/ convertible securities) in last 18 months from the date of the Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days ("Primary Issue").

^{^^}There were no secondary transactions in last 18 months from the date of the Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transaction").

PROPOSED LISTING: MAY 29, 2026*

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), 40% of the Anchor Investor Portion shall be reserved for, (i) 33.33% shall be available for allocation to domestic Mutual Funds, and (ii) 6.67% for life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in (i) above, the allocation may be made to domestic Mutual Funds in accordance with the SEBI ICDR Regulations. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (1/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than 2 lots and upto such lots equivalent to not more than ₹ 10.00 Lakhs and 2/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than ₹ 10.00 Lakhs and the unsubscribed portion in either of the sub categories, could be allocated to applicants in the other sub-category of NIBs) and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Investors using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 341 of the Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of this Issue, the designated Stock Exchange will be the National Stock Exchange of India Limited. The trading is proposed to be commenced on May 29, 2026 *

*Subject to the receipt of listing and trading approval from the NSE ("NSE EMERGE").

SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on Wednesday, May 20, 2026. The Company received 18 Anchor Investors applications for 20,43,600 Equity Shares. The Anchor Investor Allocation price was finalized at ₹343/- per Equity Share. A total of 17,81,200 Equity Shares were allotted under the Anchor Investors portion aggregating to ₹ 61,09,51,600.00

The Issue (excluding Anchor Investors Portion) received 2,36,894 Applications for 42,80,91,600 Equity Shares (after considering invalid bids, Other than RC10 Transaction declined by Investors, RC10 Mandate not accepted by Investors and Withdrawal/ Cancelled Bids reported by SCSB and rejections) resulting 95.73 times subscription (including reserved portion of market maker and excluding anchor investor portion). The details of the Applications received in the Issue from various categories are as under (before rejections):

Detail of the Applications Received (excluding Anchor Investors Portion):

| Sr. No. | Category | Number of Applications | No. of Equity Shares applied | Equity Shares Reserved as per Prospectus | No. of times Subscribed | Amount (Rs.) |
|---------|--|------------------------|------------------------------|--|-------------------------|--------------------------|
| 1. | Individual Investors | 1,86,599 | 14,92,79,200 | 20,79,200 | 71.80 | 51,19,89,82,000 |
| 2. | Non-institutional Investors (More than 2 lots and up to ₹10 lakhs) | 18,802 | 2,44,19,600 | 2,97,200 | 82.17 | 8,37,28,52,000 |
| 3. | Non-institutional Investors (above ₹10 lakhs) | 31,365 | 10,70,06,400 | 5,94,400 | 180.02 | 36,70,29,09,200 |
| 4. | Qualified Institutional Bidders (excluding Anchors Investors) | 127 | 14,70,73,200 | 11,88,000 | 123.80 | 50,44,61,07,600 |
| 5. | Market Maker | 1 | 3,13,200 | 3,13,200 | 1.00 | 10,74,27,600 |
| | Total | 2,36,894 | 42,80,91,600 | 44,72,000 | 95.73 | 1,46,82,82,78,400 |

Final Demand:

A summary of the final demand as per NSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

| Sr. No. | Bid Price | No. of Equity Shares | % to Total | Cumulative Share Total | Cumulative % of Total |
|---------|-----------|----------------------|------------|------------------------|-----------------------|
| 1 | 326 | 3,23,200 | 0.07% | 3,23,200.00 | 0.07% |
| 2 | 327 | 22,000 | 0.00% | 3,45,200.00 | 0.08% |
| 3 | 328 | 4,800 | 0.00% | 3,50,000.00 | 0.08% |
| 4 | 329 | 6,800 | 0.00% | 3,56,800.00 | 0.08% |
| 5 | 330 | 48,400 | 0.01% | 4,05,200.00 | 0.09% |

| | | | | | |
|----|--------------|---------------------|----------------|-----------------|---------|
| 6 | 331 | 1,600 | 0.00% | 4,06,800.00 | 0.09% |
| 7 | 332 | 4,000 | 0.00% | 4,10,800.00 | 0.09% |
| 8 | 333 | 17,600 | 0.00% | 4,28,400.00 | 0.10% |
| 9 | 334 | 8,400 | 0.00% | 4,36,800.00 | 0.10% |
| 10 | 335 | 42,400 | 0.01% | 4,79,200.00 | 0.11% |
| 11 | 336 | 7,200 | 0.00% | 4,86,400.00 | 0.11% |
| 12 | 337 | 800 | 0.00% | 4,87,200.00 | 0.11% |
| 13 | 338 | 10,000 | 0.00% | 4,97,200.00 | 0.11% |
| 14 | 339 | 10,800 | 0.00% | 5,08,000.00 | 0.11% |
| 15 | 340 | 48,800 | 0.01% | 5,56,800.00 | 0.12% |
| 16 | 341 | 84,800 | 0.02% | 6,41,600.00 | 0.14% |
| 17 | 342 | 1,75,200 | 0.04% | 8,16,800.00 | 0.18% |
| 18 | 343 | 44,75,67,200 | 99.82% | 44,83,84,000.00 | 100.00% |
| | Total | 44,83,84,000 | 100.00% | | |

The Basis of Allotment was finalized in consultation with the designated Stock Exchange, being National Stock Exchange of India Limited ("NSE EMERGE") on May 26, 2026.

1) Allotment to Individual Investors (After Rejections):

The Basis of Allotment to the Individual Investors, who have Bid at or above the Issue Price of ₹ 343/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 70.27 times i.e. for 14,61,12,800 Equity Shares. The total number of Equity Shares Allotted in this category is 20,79,200 Equity to 2,599 successful applicants. The details of the Basis of Allotment of the said category are as under:

| No. of Shares Applied for (Category wise) | No. of Applications Received | % of Total | Total No. of Shares Applied | % to Total | No. of Equity Shares Allotted per Applicant | Ratio | Total No. of shares allocated/ allotted |
|---|------------------------------|------------|-----------------------------|------------|---|-------------|---|
| 800 | 182641 | 100.00 | 14,61,12,800 | 100.00 | 800 | 2599:182641 | 20,79,200 |

Continued on next page

Rising capex, demand energise power stocks

Heavy order inflows, earnings visibility drive sectorwide buying

DEEPAK KORGAONKAR
Mumbai, 28 May



On a roll

| | CMP (₹) | 1-day chg (%) | All-time high (₹)* |
|---------------------------------|-----------------|---------------|--------------------|
| ABB India | 7,217.3 | 6.0 | 9,021.9 |
| Adani Power | 248.8 | 1.7 | 248.8 |
| Bharat Heavy Electricals | 422.6 | 1.1 | 422.6 |
| CG Power & Industrial Solutions | 935.1 | 6.4 | 935.1 |
| Siemens Energy India | 3,773.0 | 9.0 | 3,773.0 |
| GE Vernova T&D India | 5,100.3 | 5.2 | 5,100.3 |
| JSW Energy | 601.8 | 4.5 | 791.8 |
| Hitachi Energy India | 37,556.0 | 4.4 | 37,556.0 |
| Siemens | 3,880.6 | 5.6 | 3,968.7 |
| Thermax | 4,588.7 | 3.5 | 5,663.8 |
| BSE Power | 8,497.1 | 3.3 | 8,768.0 |
| Sensex | 75,867.8 | -0.2 | 85,836.1 |

Current market price (CMP) as on May 27; *On closing basis on BSE Source: Bloomberg

Shares of power generation-related companies were on a roll on Wednesday, with the BSE Power index hitting a new high of 8,497, driven by strong demand and robust order books. Over the past two months, the BSE Power index has surged 24 per cent.

The BSE Power index was the top gainer among sectoral indices, rising 3.3 per cent compared to a 0.2 per cent decline in the BSE Sensex. Six of the 15 stocks in the index hit their respective all-time highs — Adani Power, Bharat Heavy Electricals, CG Power and Industrial Solutions, GE Vernova T&D India, Hitachi Energy India, and Siemens Energy India.

Among individual stocks, Siemens Energy India soared 9 per cent, while CG Power and Industrial Solutions rallied 6.4 per cent, followed by ABB at 6 per cent. GE Vernova T&D India gained 5.2 per cent, followed by JSW Energy at 4.5 per cent and Thermax at 3.5 per cent.

Following its fourth-quarter (January-March/Q4) results for 2025-26 (FY26), Hitachi Energy India highlighted a strong multi-year growth outlook driven by rising power demand, renewable energy integration, electrification, and data centre expansion. The company said its total order backlog surged to ₹29,555 crore in Q4FY26, providing strong revenue visibility for several quarters.

The company has secured over ₹20,000 crore worth of high-voltage direct current (HVDC) orders and is currently executing two mega 6-gigawatt HVDC projects — Khavda-Nagpur and Bhadla-Fatehpur. Hitachi Energy also announced an additional capital expenditure of ₹2,000 crore for its Vadodara transformer facility, taking cumulative announced investments to ₹4,000 crore.

In Q4 of calendar year 2025, the company's revenue rose 46.2 per cent year-on-year (Y-o-Y) to ₹2,754

crore, while profit after tax jumped 80 per cent Y-o-Y to ₹330 crore.

Adani Green Energy commissioned a cumulative 3.37 gigawatt-hour (GWh) battery energy storage system at Khavda, Gujarat, making it the world's largest single-location battery storage deployment outside China and among the fastest executed globally. The project, completed within 10 months, included 1.37 GWh commissioned in March 2026 and is aimed at strengthening grid reliability and enabling round-the-clock renewable power supply. The company plans to add over 10 GWh of battery storage capacity in 2026-27 (FY27) and scale total storage capacity to 50 GWh over the next five years.

CG Power and Industrial Solutions said order inflows remained strong during Q4FY26, with several key wins taking the order backlog up 59 per cent Y-o-Y to ₹15,719 crore,

offering strong revenue visibility for FY27. The company is well-positioned to benefit from strong industry tailwinds, particularly in the power systems segment, where rising investments in renewable energy, data centres, and thermal power are driving demand for transformers and switchgear.

To capitalise on this momentum, the company recently completed a major expansion of its power transformer capacity to 50,000 megavolt-amperes (MVA) from 17,000 MVA and is working to increase it further to 65,000 MVA in the near term.

FY27 is expected to be a year of accelerating earnings delivery. The sizeable projects commissioned during FY26 are expected to stabilise and contribute to full-year earnings before interest, tax, depreciation, and amortisation, driving a meaningful step-up in the company's financial performance.



How to prevent rejection of EV insurance claim

SANJAY KUMAR SINGH & KARTHIK JEROME

Online insurance portal Policybazaar has reported strong growth in electric vehicle (EV) insurance on its platform. Sales rose 670 per cent between 2024-25 (FY25) and FY26, though on a very small base. EVs currently account for 1 per cent of all the vehicles insured on its platform.

As EV adoption rises, owners need to understand the claim-related risks linked to batteries, charging practices, maintenance, and compliance.

Use approved batteries and chargers

One of the most common reasons for rejection of EV insurance claims is the use of non-original equipment manufacturer (OEM) or unauthorised chargers or batteries. OEMs especially warn against using unauthorised fast chargers.

"Non-OEM or non-approved chargers may have unstable voltage. They may overheat the battery, damage the battery management system (BMS), and increase the risk of a fire," says Shilpa Arora, cofounder and chief operating officer,

Violations that cause claim rejection

- Driving under the influence of alcohol or drugs
- Driving without a valid licence
- Claims made after policy lapse
- Using privately insured EV for ride sharing or delivery

Insurance Samadhan.

If an investigation shows that incompatible charging equipment caused battery swelling, a short circuit, or other damage, the insurer may reject the claim.

Follow charging rules

OEMs recommend charging within permitted voltage and current limits. Owners must use proper electrical installations and compatible connectors and adapters.

Owners should also adhere to battery protection practices. "They must protect the battery from water and extreme temperatures during charging," says Sandeep Saraf, head of motor renewals and claims, Policybazaar.

If the owner does not follow charging guidelines and the vehicle gets damaged, the insurer

may reject the claim.

Gradual decline in battery health not covered

A gradual reduction in battery efficiency over time is treated as normal degradation. "If an EV battery fails because it has degraded over time below the manufacturer's acceptable health level, the owner may have to approach the manufacturer under warranty, if eligible," says Saraf. The insurance cover will not pay for deterioration caused by natural wear and tear. Battery damage caused by an accident is covered.

Avoid unauthorised modifications

EV owners should not modify electrical systems or tamper with the vehicle's software. "If the insured modifies the vehicle and does not disclose it to the insurer, the insurer may deny claims arising from that modification," says Pradeep Funde, senior vice president, Anand Rathi Insurance Brokers. Any modification that compromises vehicle safety makes it difficult for insurers to assess the exact cause of loss and often leads to a dispute. "Unauthorised modifications affect safety and electrical integrity," says Funde.

Understand warranty and recall coverage

Customers need to understand what the OEM's warranty covers and what the vehicle's insurance policy covers.

If a manufacturing defect causes battery damage and the OEM warranty programme covers it, the insurer will not cover it. "A sudden loss of vehicle range due to internal cell failure

without external damage or accident is typically a manufacturing issue covered under the manufacturer's warranty," says Funde.

Recalls arise from safety defects, battery defects, software faults, or manufacturing issues. "In recall cases, the manufacturer is expected to repair or replace the part under the manufacturing warranty. The liability does not fall on the insurer," says Arora.

Avoid waterlogging

EV owners should protect the vehicle from severe waterlogging. "Driving through deep floodwaters or charging after heavy exposure to water may be classified as owner negligence," says Abhishek Kumar, Sebi-registered investment advisor and founder, SahajMoney.com.

Do not repair before approval

The policyholder should wait for the surveyor's inspection. "If repairs are completed before inspection, evidence may disappear and the extent or cause of damage may become unverifiable," says Arora.

Repairs before inspection also make the insurer suspect inflated billing or unrelated repairs.

Act promptly after an incident

EV owners should inform the insurer immediately after an accident so that an inspection can be carried out. "Delay may cause consequential damage and put the claim in dispute," says Funde.

Most policies require claim intimation within 24-48 hours for accidents or theft. Finally, owners should preserve evidence of the incident through photos and videos.

Lost money by scanning a QR code? Follow these steps immediately

Scanning a fake QR code to transfer money can empty your bank account within seconds. Victims may recover their money if they alert their banks and cybercrime authorities promptly.

QR code scam explained

Fraudsters send QR codes claiming they are needed to "receive"

money, process refunds, collect cashback, claim prizes or complete delivery payments.

The fraud succeeds when people enter their UPI PIN without checking the beneficiary details displayed on the payment or bank app.

Fraudsters often create urgency or panic to prevent

users from verifying details carefully.

What to do

Fraud victims should immediately call their bank or UPI app customer care and share these details:

- Transaction ID
- Amount transferred

- Date and time of payment
 - Beneficiary name and UPI ID
 - Screenshots of the transaction or QR code
- They should also call 1930, the national cybercrime financial fraud helpline. A QR code is meant for making payments: Users generally do not need to scan one to receive money.

Read full report here: mybs.in/zg6Hks4

COMPILED BY AMIT KUMAR

Continued from previous page

2) Allotment to Non-Institutional Investors (More than 2 lots and up to ₹ 10,00,000) (After Rejections):

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹ 343/- or above per Equity Share was finalized in consultation with NSE. The category has been subscribed to the extent of 80.67 times i.e. for 2,39,74,800 Equity Shares (after rejection). The total number of Equity Shares Allotted in this category is 2,97,200 Equity Shares to 247 successful applicants. The details of the Basis of Allotment of the said category are as under:

| No. of Shares applied for (Category wise) | Number of applications received | % to total | Total No. of Shares applied in each category | % to total | No of equity shares | Ratio of allottees to applicants | Total No. of shares allocated/allotted |
|---|---------------------------------|---------------|--|---------------|---------------------|----------------------------------|--|
| 1200 | 16,550 | 89.67 | 1,98,60,000 | 82.83 | 2,66,507.37 | 222:16,550 | 2,66,400 |
| 1600 | 727 | 3.93 | 11,63,200 | 4.85 | 11,707.00 | 9:727 | 10,800 |
| 2000 | 283 | 1.53 | 5,66,000 | 2.36 | 4,557.20 | 4:283 | 4,800 |
| 2400 | 308 | 1.66 | 7,39,200 | 3.08 | 4,959.77 | 4:308 | 4,800 |
| 2800 | 588 | 3.18 | 16,46,400 | 6.86 | 9,468.66 | 8:588 | 9,600 |
| 2 out of 25 Successful Allottees from Serial no 2-5 will get Additional 1 lot of 400 shares | | | | | | 2:25 | 800 |
| TOTAL | 18,456 | 100.00 | 2,39,74,800 | 100.00 | 2,97,200 | | 2,97,200 |

3) Allotment to Non-Institutional Investors (More than ₹ 10,00,000)

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹ 343/- or above per Equity Share was finalized in consultation with NSE. The category has been subscribed to the extent of 178.11 times i.e. for 10,58,66,000 Equity Shares (after rejection). The total number of Equity Shares Allotted in this category is 5,94,400 Equity to 495 successful applicants. The details of the Basis of Allotment of the said category are as under:

| No. of Shares applied for (Category wise) | Number of applications received | % to total | Total No. of Shares applied in each category | % to total | Proportionate shares available | Ratio of allottees to applicants | Total No. of shares allocated/allotted |
|--|---------------------------------|------------|--|------------|--------------------------------|----------------------------------|--|
| 3,200 | 29,597 | 95.05 | 9,47,10,400 | 89.46 | 5,65,019.81 | 471:29,597 | 5,65,200 |
| 3,600 | 498 | 1.59 | 17,92,800 | 1.69 | 9,507.04 | 8:498 | 9,600 |
| 4,000 | 273 | 0.87 | 10,92,000 | 1.03 | 5,211.69 | 4:273 | 4,800 |
| 4,400 | 126 | 0.40 | 5,54,400 | 0.52 | 2,405.40 | 1:63 | 2,400 |
| 4,800 | 62 | 0.19 | 2,97,600 | 0.28 | 1,183.61 | 1:62 | 1,200 |
| 5,200 | 85 | 0.27 | 4,42,000 | 0.41 | 1,622.69 | 1:85 | 1,200 |
| 5,600 | 55 | 0.17 | 3,08,000 | 0.29 | 1,049.97 | 1:55 | 1,200 |
| 6,000 | 55 | 0.17 | 3,30,000 | 0.31 | 1,049.97 | 1:55 | 1,200 |
| 6,400 | 81 | 0.26 | 5,18,400 | 0.48 | 1,546.33 | 1:81 | 1,200 |
| 7,200 | 38 | 0.12 | 2,73,600 | 0.25 | 725.44 | 1:38 | 1,200 |
| 11,200 | 4 | 0.01 | 44,800 | 0.04 | 76.36 | 0:0 | - |
| 15,200 | 1 | 0.00 | 15,200 | 0.01 | 19.09 | 0:0 | - |
| 20,400 | 1 | 0.00 | 20,400 | 0.01 | 19.09 | 0:0 | - |
| 29,200 | 4 | 0.01 | 1,16,800 | 0.11 | 76.36 | 0:0 | - |
| 54,000 | 1 | 0.00 | 54,000 | 0.05 | 19.09 | 0:0 | - |
| 1,46,000 | 1 | 0.00 | 1,46,000 | 0.13 | 19.09 | 0:0 | - |
| 4 out of 266 un-successful Allottees from Serial no 10 & 12 to 73 will get Additional 1 lot of 1200 shares | | | | | | 4:266 | 4800 |
| 1 out of 495 successful Allottees will get Additional 1 lot of 400 shares | | | | | | 1:495 | 400 |

INVESTORS, PLEASE NOTE

The details of the allotment made has been hosted on the website of the Registrar to the Issue, Purva Sharegistry (India) Private Limited

TRACK RECORD OF BOOK RUNNING LEAD MANAGER: The BRLMs associated with the Issue have handled 79 Public Issues in the past three years, out of which 8 issues were closed below the Issue Price on listing date:

| Name of BRLM | Total Issue | | Issue closed below IPO Price on listing date |
|--|-------------|-----------|--|
| | Mainboard | SME | |
| Hem Securities Limited | 2 | 62 | 4 (SME) |
| Share India Capital Services Private Limited | - | 14 | 4 |
| Common* | - | 1 | - |
| Total | 2 | 77 | 8 |

* Issue in which both BRLMs were involved.

All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole Bidder Serial number of the ASBA form, number of Equity Shares bid for, Bidder DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and copy of the Acknowledgment Slip received from the Designated Intermediary and payment details at the address given below:

Purva Sharegistry (India) Private Limited
 Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011
 Tel. No.: 91 22 41343255/41343271
 Email: newissue@purvashare.com
 Website: www.purvashare.com
 Contact Person: Deepali Gaonkar
 SEBI Registration No.: INR000001112

On behalf of Board of Directors
Q-Line Biotech Limited
 Sd/-
Akhand Pratap Singh
 Company Secretary and Compliance Officer

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF Q-LINE BIOTECH LIMITED

Disclaimer: Q-Line Biotech Limited has filed the Prospectus with the RoC on May 26, 2026 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of the BRLMs, Hem Securities Limited and Share India Capital Services Private Limited at www.hemsecurities.com and www.shareindia.com and the Company at: www.qlinebiotech.com and shall also be available on the website of the NSE and SEBI. Investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 20 of the Prospectus. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public Issuing in the United States.

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



[Please scan this QR Code to view the Prospectus]

Q-LINE BIOTECH LIMITED

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE")

Our Company was originally incorporated as "POCT Services Private Limited" on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to "Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to "Q-Line Biotech Limited", and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled "History and Corporate Structure" beginning on page 152 of the Prospectus.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012

Tel.: +91 522-2435570, **E-mail:** compliance@qlinebiotech.com ; **Website:** www.qlinebiotech.com

CIN: U74120UP2010PLC042528 ; **Contact Person:** Akhand Pratap Singh, Company Secretary & Compliance Officer

OUR PROMOTERS: SAURABH GARG, AMITA GARG, AYUSH GARG, AJAY KUMAR MAHANTY AND ABHAY AGRAWAL

Our Company has filed the Prospectus dated May 26, 2026 with ROC and thereafter with SEBI and the stock exchange and Equity Shares are proposed to be listed on SME Platform of NSE (NSE Emerge) on May 29, 2026.

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE (NSE EMERGE)."

BRIEF DESCRIPTION OF THE BUSINESS OF THE COMPANY

We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of our Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF UPTO 62,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF Q-LINE BIOTECH LIMITED ("OUR COMPANY" OR "QLBL" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹333 PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ 21,448.48 LAKHS ("PUBLIC ISSUE") OUT OF WHICH 3,13,200 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE FOR CASH, AGGREGATING ₹ 1,074.28 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 59,40,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ 20,374.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.81 % AND 25.46 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS RS. 10/- AND ISSUE PRICE IS RS. 343/- EACH. THE ISSUE PRICE IS 34.30 TIMES OF THE FACE VALUE OF THE EQUITY SHARE

ANCHOR INVESTOR ISSUE PRICE: RS. 343/- PER EQUITY SHARE.

THE ISSUE PRICE IS 34.30 TIMES OF THE FACE VALUE

BID/ ISSUE PERIOD

ANCHOR INVESTOR BIDDING DATE: WEDNESDAY, MAY 20, 2026

BID/ ISSUE OPENED ON: THURSDAY, MAY 21, 2026

BID/ ISSUE CLOSED ON: MONDAY, MAY 25, 2026

RISKS TO INVESTORS:

- Any disruption, stoppage, slowdown or shutdown in our manufacturing facilities or process or research and development activities could adversely affect our business, financial condition, cash flows and results of operations.
- Any delay, interruption or reduction in the supply of our raw materials, trade goods from our suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of our products and have an adverse effect on our business, financial condition, cash flows and results of operations.
- Our business is dependent on the sale of our products through distributors which also include our group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of our products and could negatively impact our business, results of operations, financial conditions and cash flows.
- We are dependent on certain key suppliers to procure a significant portion of our Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in our operations, which could have an adverse effect on our business, financial condition, results of operations and cash flows.
- We are required to obtain, maintain or renew our statutory and regulatory approvals, licenses, and registrations to operate our business.
- For manufacturing of our machines and reagents, we are dependent on the agreement with the European companies, any failure to renew the agreement or entering into the agreement on the terms which are not favourable for us may impact our business operations, financial condition and cash flows.
- Our erstwhile associate company i.e. POCT Science House Private Limited and our promoters namely Saurabh Garg and Amita Garg have been subject to search and seizure operations by the Income-tax Department and any adverse outcome of these proceedings may adversely affect our financial condition.
- Our operations are concentrated in North India, and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.
- Our Company requires a significant amount of working capital for continuing growth. Our inability to meet our working capital requirements may adversely affect our results of operations.
- We are subject to risks arising from exchange rate fluctuations.
- The BRLMs associated with the Issue have handled 79 Public Issues in the past three years, out of which 8 issues were closed below the Issue Price on listing date:

- Average cost of acquisition of Equity Shares held by the Promoters is

| Sr. No. | Name of Promoter | No. of Shares held | Average Cost of Acquisition (in ₹) |
|---------|--------------------|--------------------|------------------------------------|
| 1. | Saurabh Garg | 1,01,91,000 | 0.04 |
| 2. | Amita Garg | 39,37,480 | 0.00 |
| 3. | Ayush Garg | 31,500 | 0.00 |
| 4. | Ajay Kumar Mahanty | 7,50,000 | 18.34 |
| 5. | Abhay Agrawal | 7,56,010 | 0.00 |

- The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end (₹343) of the Price Band is 11.98

- Weighted Average Return on Net worth for Fiscals 2025, 2024 and 2023 is 23.17%.

- The Weighted average cost of acquisition of all Equity Shares transacted in the last one year, 18 months and three years from the date of Prospectus is as given below:

| Period | Weighted Average Cost of Acquisition (in Rs.) | Cap Price (₹343) is 'X' times the Weighted Average Cost of Acquisition | Range of acquisition price: Lowest Price – Highest Price (in Rs.) |
|---|---|--|---|
| Last one year, Last 18 Months, three years preceding the date of the Prospectus | 17.88 | 19.18 | 0-343 |

- The Weighted average cost of acquisition compared to Floor Price and Cap Price.

| Types of transactions | Weighted average cost of acquisition (₹ per Equity Shares of face value of Rs. 10/-) | Floor price (i.e. ₹ 326) | Cap price (i.e. ₹ 343) |
|---|--|--------------------------|------------------------|
| Weighted average cost of acquisition of primary / new Issue | NA [^] | NA [^] | NA [^] |
| Weighted average cost of acquisition for secondary sale / acquisition | NA ^{^^} | NA ^{^^} | NA ^{^^} |
| Weighted average cost of acquisition of primary issuances/ secondary transactions | 17.89 | 18.22 | 19.17 |

Note:

[^]There were no primary/ new issue of shares (equity/ convertible securities) in last 18 months from the date of the Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days ("Primary Issue").

^{^^}There were no secondary transactions in last 18 months from the date of the Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transaction").

PROPOSED LISTING: MAY 29, 2026*

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), 40% of the Anchor Investor Portion shall be reserved for, (i) 33.33% shall be available for allocation to domestic Mutual Funds, and (ii) 6.67% for life insurance companies and pension funds, subject to valid Bids being received at or above the Issue Price. In the event of under-subscription in (ii) above, the allocation may be made to domestic Mutual Funds in accordance with the SEBI ICDR Regulations. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (1/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than 2 lots and upto such lots equivalent to not more than ₹ 10.00 Lakhs and 2/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than ₹ 10.00 Lakhs and the unsubscribed portion in either of the sub categories, could be allocated to applicants in the other sub-category of NIBs) and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Investors using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 341 of the Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of this Issue, the designated Stock Exchange will be the National Stock Exchange of India Limited. The trading is proposed to be commenced on May 29, 2026 *

*Subject to the receipt of listing and trading approval from the NSE ("NSE EMERGE").

SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on Wednesday, May 20, 2026. The Company received 18 Anchor Investors applications for 20,43,600 Equity Shares. The Anchor Investor Allocation price was finalized at ₹343/- per Equity Share. A total of 17,81,200 Equity Shares were allotted under the Anchor Investors portion aggregating to ₹ 61,09,51,600.00

The Issue (excluding Anchor Investors Portion) received 2,36,894 Applications for 42,80,91,600 Equity Shares (after considering invalid bids, Other than RC10 Transaction declined by Investors, RC10 Mandate not accepted by Investors and Withdrawal/ Cancelled Bids reported by SCSB and rejections) resulting 95.73 times subscription (including reserved portion of market maker and excluding anchor investor portion). The details of the Applications received in the Issue from various categories are as under (before rejections):

Detail of the Applications Received (excluding Anchor Investors Portion):

| Sr. No. | Category | Number of Applications | No. of Equity Shares applied | Equity Shares Reserved as per Prospectus | No. of times Subscribed | Amount (Rs.) |
|---------|--|------------------------|------------------------------|--|-------------------------|--------------------------|
| 1. | Individual Investors | 1,86,599 | 14,92,79,200 | 20,79,200 | 71.80 | 51,19,89,82,000 |
| 2. | Non-institutional Investors (More than 2 lots and up to ₹10 lakhs) | 18,802 | 2,44,19,600 | 2,97,200 | 82.17 | 8,37,28,52,000 |
| 3. | Non-institutional Investors (above ₹10 lakhs) | 31,365 | 10,70,06,400 | 5,94,400 | 180.02 | 36,70,29,09,200 |
| 4. | Qualified Institutional Bidders (excluding Anchors Investors) | 127 | 14,70,73,200 | 11,88,000 | 123.80 | 50,44,61,07,600 |
| 5. | Market Maker | 1 | 3,13,200 | 3,13,200 | 1.00 | 10,74,27,600 |
| | Total | 2,36,894 | 42,80,91,600 | 44,72,000 | 95.73 | 1,46,82,82,78,400 |

Final Demand:

A summary of the final demand as per NSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

| Sr. No. | Bid Price | No. of Equity Shares | % to Total | Cumulative Share Total | Cumulative % of Total |
|---------|-----------|----------------------|------------|------------------------|-----------------------|
| 1 | 326 | 3,23,200 | 0.07% | 3,23,200.00 | 0.07% |
| 2 | 327 | 22,000 | 0.00% | 3,45,200.00 | 0.08% |
| 3 | 328 | 4,800 | 0.00% | 3,50,000.00 | 0.08% |
| 4 | 329 | 6,800 | 0.00% | 3,56,800.00 | 0.08% |
| 5 | 330 | 48,400 | 0.01% | 4,05,200.00 | 0.09% |

| | | | | | |
|----|--------------|---------------------|----------------|-----------------|---------|
| 6 | 331 | 1,600 | 0.00% | 4,06,800.00 | 0.09% |
| 7 | 332 | 4,000 | 0.00% | 4,10,800.00 | 0.09% |
| 8 | 333 | 17,600 | 0.00% | 4,28,400.00 | 0.10% |
| 9 | 334 | 8,400 | 0.00% | 4,36,800.00 | 0.10% |
| 10 | 335 | 42,400 | 0.01% | 4,79,200.00 | 0.11% |
| 11 | 336 | 7,200 | 0.00% | 4,86,400.00 | 0.11% |
| 12 | 337 | 800 | 0.00% | 4,87,200.00 | 0.11% |
| 13 | 338 | 10,000 | 0.00% | 4,97,200.00 | 0.11% |
| 14 | 339 | 10,800 | 0.00% | 5,08,000.00 | 0.11% |
| 15 | 340 | 48,800 | 0.01% | 5,56,800.00 | 0.12% |
| 16 | 341 | 84,800 | 0.02% | 6,41,600.00 | 0.14% |
| 17 | 342 | 1,75,200 | 0.04% | 8,16,800.00 | 0.18% |
| 18 | 343 | 44,75,67,200 | 99.82% | 44,83,84,000.00 | 100.00% |
| | Total | 44,83,84,000 | 100.00% | | |

The Basis of Allotment was finalized in consultation with the designated Stock Exchange, being National Stock Exchange of India Limited ("NSE EMERGE") on May 26, 2026.

1) Allotment to Individual Investors (After Rejections):

The Basis of Allotment to the Individual Investors, who have Bid at or above the Issue Price of ₹ 343/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 70.27 times i.e. for 14,61,12,800 Equity Shares. The total number of Equity Shares Allotted in this category is 20,79,200 Equity to 2,599 successful applicants. The details of the Basis of Allotment of the said category are as under:

| No. of Shares Applied for (Category wise) | No. of Applications Received | % of Total | Total No. of Shares Applied | % to Total | No. of Equity Shares Allotted per Applicant | Ratio | Total No. of shares allocated/ allotted |
|---|------------------------------|------------|-----------------------------|------------|---|-------------|---|
| 800 | 182641 | 100.00 | 14,61,12,800 | 100.00 | 800 | 2599:182641 | 20,79,200 |

Continued on next page

प. एशिया संकट से छोटी-मझोली दवा कंपनियों के मुनाफे पर दबाव

दवा निर्माताओं, सूक्ष्म, लघु और मध्यम उद्यमों की लाभप्रदता, कार्यशील पूंजी पर बढ़ा दबाव

संकेत कोल
नई दिल्ली, 28 मई

पश्चिम एशिया में संघर्ष को तीन महीने पूरे हो रहे हैं और इसके कारण आपूर्ति श्रृंखला में लंबे समय से चली आ रही बाधा भारतीय दवा विनिर्माताओं, विशेष रूप से सूक्ष्म, लघु और मध्यम उद्यमों (एमएसएमई) की लाभप्रदता पर 3 से 5 फीसदी और कार्यशील पूंजी पर 12 से 15 फीसदी का असर पड़ने की आशंका है।

ट्रेजिक्स के मुख्य कार्याधिकारी और सह-संस्थापक हेरेश कलकत्तावाला ने कहा, 'उद्योग विश्लेषण के अनुसार कार्यशील पूंजी पर लगभग 12 से 15 फीसदी का प्रभाव पड़ा है, जिससे निवेश पर रिटर्न स्वतः गिर गया है। प्रभावी रूप से लघु एवं मध्यम उद्यमों को अपने व्यवसाय के स्तर को बनाए रखने के लिए पहले की तुलना में परिचालन में 12 से 15 फीसदी अधिक पूंजी लगाने की जरूरत पड़ सकती है।'

उन्होंने आगे कहा कि छोटी कंपनियों के लिए निवेश पर रिटर्न 5 से 5.5 फीसदी तक घट सकता है जिसके परिणामस्वरूप लाभप्रदता में 3 से 5 फीसदी की कमी आ सकती है। इन व्यवधानों से फार्मा कंपनियों पर पहले से मौजूद दबाव और बढ़ रहा है, जिसमें महंगे पेट्रोलियम आधारित कच्चे माल, बढ़े हुए माल ढुलाई और युद्ध-जोखिम बीमा शुल्क और शिपिंग में लगने वाला लंबा समय शामिल है।

हिमाचल प्रदेश की एक एमएसएमई दवा फर्म के एक कार्याधिकारी ने बिज़नेस स्टैंडर्ड को बताया, 'ऊर्जा की लागत में भी काफी वृद्धि हुई है जिससे सॉल्वेंट, इंटरमीडिएट और अन्य महत्वपूर्ण फार्मा सामग्री महंगी हो गई है।' उन्होंने कहा कि सक्रिय फार्मास्यूटिकल सामग्री (एपीआई), सॉल्वेंट और पैकेजिंग सामग्री की कीमतें कुछ मामलों में 200 फीसदी तक बढ़ गई हैं, जिसके चलते हिमाचल प्रदेश ड्रग मैनुफैक्चरर्स एसोसिएशन ने राष्ट्रीय औषधि मूल्य निर्धारण प्राधिकरण से हस्तक्षेप करने की मांग की है।

फार्मा से जुड़े एक अन्य कार्याधिकारी ने बताया कि एपीआई आपूर्तिकर्ता मुंबई की बीएसएसएफ इंडिया ने हाल ही में कुछ



दवा कंपनियों को मुनाफे में 5 फीसदी तक की गिरावट का सामना करना पड़ सकता है

एक्सिपिएंट और कुछ एपीआई के दाम 20 फीसदी तक बढ़ाने की घोषणा की है। उन्होंने कहा, 'ईंधन की लागत में 20 से 30 फीसदी की वृद्धि के साथ प्रभावित मार्गों पर माल ढुलाई दरों में वृद्धि ने निर्यात-उन्मुख एमएसएमई दवा फर्मों की मुश्किलें बढ़ा दी हैं।' पिछले तीन महीनों में पश्चिम एशिया जाने वाले कुछ कंटेनर पर माल ढुलाई दर कई गुना बढ़ गई है, जिसका कारण नए मार्ग से मालवहन, उच्च युद्ध-जोखिम बीमा प्रीमियम और शिपिंग से जुड़ी बाधाएं हैं।

एपीआई के अलावा दवा बनाने में उपयोग होने वाले अन्य प्रमुख कच्चा माल जैसे मेथनॉल, प्रोपलीन और अमोनिया की अपूर्ति में भी बाधा आ रही है। औषधि विभाग के एक वरिष्ठ अधिकारी ने कहा, 'मेथनॉल बड़ी समस्या नहीं है क्योंकि हमें हाल ही में पश्चिम एशिया से 2 से 3 शिपमेंट मिले हैं।' हालांकि उन्होंने कहा कि भारतीय दवा विनिर्माताओं को प्रति माह लगभग 15,000 टन मेथनॉल की आवश्यकता होती है।

क्रिसिल ने कहा कि कच्चे तेल और वैश्विक आपूर्ति श्रृंखलाओं पर निर्भर क्षेत्र पश्चिम एशिया संघर्ष से उत्पन्न होने वाले

व्यवधानों के प्रति संवेदनशील बने हुए हैं। दवा उद्योग उच्च माल ढुलाई और लॉजिस्टिक लागत, पेट्रोलियम आधारित कच्चे माल और सॉल्वेंट की बढ़ती कीमतों तथा शिपिंग व्यवधानों और ऊंचे कच्चे तेल की कीमतों के कारण दबाव महसूस कर रहा है। क्रिसिल ने कहा कि फार्मा निर्यातकों को रुपये में गिरावट से आंशिक रूप से लाभ हो सकता है।

हालांकि बड़ी चिंता अन्य कच्चे माल की आपूर्ति से जुड़ा है। उदाहरण के लिए अर्पयॉल प्रोपलीन आपूर्ति इबुप्रोफेन के उत्पादन को पूरी तरह से रोक सकती है, जिससे बड़े पैमाने पर दर्द और बुखार की दवाओं पर असर पड़ेगा। अधिकारी ने कहा, 'हमने यह सुनिश्चित करने का काम किया है कि प्रोपलीन की पर्याप्त आपूर्ति हो।'

औषधि विभाग ने दवा विनिर्माताओं के लिए अमोनिया की आपूर्ति सुनिश्चित करने के लिए पेट्रोलियम और प्राकृतिक गैस मंत्रालय तथा उर्वरक विभाग से भी समर्थन मांगा है। दवा विनिर्माताओं को हर महीने लगभग 12,000 टन अमोनिया की आवश्यकता होती है।

कलकत्तावाला ने कहा, 'खाड़ी और

पश्चिम एशियाई क्षेत्र इन कच्चे माल का प्रमुख आपूर्तिकर्ता है इसलिए लंबे समय तक भू-राजनीतिक व्यवधान भारतीय दवा विनिर्माताओं की लागत और आपूर्ति में अनिश्चितता को बढ़ा सकता है।'

इससे आवश्यक दवाओं के बनाने की लागत में वृद्धि हो सकती है और कार्यशील पूंजी पर दबाव बढ़ सकता है, विशेष रूप से छोटे फार्मा निर्यातकों के लिए।

हालांकि विशेषज्ञों ने कहा कि बड़ी चिंता तत्काल राष्ट्रव्यापी दवा की कमी नहीं है बल्कि छोटे दवा विनिर्माताओं के लिए स्थिर मूल्य निर्धारण और निर्बाध आपूर्ति प्रतिबद्धताओं को बनाए रखने में बढ़ती कठिनाई है।

अधिकारी ने कहा कि बड़ी कंपनियों ने पिछले साल दिसंबर में सरकार द्वारा न्यूनतम आयात मूल्य की शुरुआत के समय सस्ती आयात, विशेष रूप से बीटा-लैक्टम का, पहले से स्टॉक कर लिया था।

कलकत्तावाला ने कहा कि बड़ी दवा कंपनियों के पास वर्तमान में आपूर्ति श्रृंखला में एपीआई का लगभग 2 से 3 महीने का स्टॉक और फॉर्मूलेशन का 4 से 5 महीने का स्टॉक उपलब्ध हो सकता है। हालांकि उन्होंने कहा, 'एमएसएमई फर्मों कार्यशील पूंजी की बाधाओं और सीमित भंडारण क्षमता के कारण आम तौर पर 3 से 6 सप्ताह के स्टॉक के साथ काम करती हैं।'

छोटे फर्मों में बड़ी कंपनियों की तुलना में उत्पादों के दाम बढ़ाने की कम क्षमता, कम इन्वेंट्री और नकदी प्रवाह तंग होने के कारण स्टॉक पर दबाव और बढ़ने की आशंका है। कलकत्तावाला ने कहा, 'फिलहाल कमी जैसी स्थिति नहीं है लेकिन पश्चिम एशिया में लंबे समय तक व्यवधान धीरे-धीरे इन्वेंट्री कम कर सकता है।'

हरियाणा की एक फार्मा एमएसएमई ने कहा कि एमोक्सिसिलिन, एजिथ्रोमाइसिन और रिफैमिसिन जैसे एंटीबायोटिक्स एसीटोन और मेथिलीन डाइक्लोराइड जैसे सॉल्वेंट पर अपनी निर्भरता के कारण ज्यादा संवेदनशील है। यह मेटफॉर्मिन और एटोरवास्टेटिन जैसी उच्च-मात्रा वाली पुरानी दवाओं पर भी लागू होता है जहां प्रति किलोग्राम थोड़ी सी भी वृद्धि लागत बढ़ा देती है।

भू-राजनीतिक, आर्थिक जोखिमों पर रिलायंस ने...

पृष्ठ 1 का शेष

जियो आईपीओ पर चुप्पी

अपनी वार्षिक रिपोर्ट में शेयरधारकों को संबोधित करते हुए आरआईएल के चेयरमैन और प्रबंध निदेशक मुकेश अंबानी ने कहा कि समूह अपने डिजिटल कारोबार को मजबूत करने के लिए सोच-समझकर कदम उठा रहा है। लेकिन इस साल जुलाई तक अपेक्षित जियो प्लेटफॉर्म लिस्टिंग के बारे में कोई जानकारी नहीं दी।

ब्लॉकरेज फर्मों के अनुसार जियो प्लेटफॉर्म के अब तक की सबसे बड़ी सार्वजनिक लिस्टिंग होने का अनुमान है और इसका मूल्यांकन 135-145 अरब डॉलर तक पहुंच सकता है। जियो के वैश्विक निवेशकों में मेटा प्लेटफॉर्म, गूगल, सऊदी अरब का पब्लिक इन्वेस्टमेंट फंड और मुंबाइला इन्वेस्टमेंट कंपनी शामिल हैं, जिन्होंने 2020 में हिस्सेदारी खरीदी थी।

अंबानी ने कहा, 'हम हितधारकों की भागीदारी बढ़ाने और जियो के दीर्घकालिक विकास में सहयोग देने वाले रणनीतिक रास्तों का मूल्यांकन करना जारी रखेंगे।' लेकिन उन्होंने आईपीओ की समयसीमा पर कोई टिप्पणी नहीं की।

जियो प्लेटफॉर्म रिलायंस जियो इन्फोकॉम की मूल कंपनी है और यह 52.4 करोड़ से अधिक ग्राहकों के साथ देश की सबसे बड़ी दूरसंचार सेवा प्रदाता है। जियो ने भारत में 5जी और एफडब्ल्यूए स्टेक का बड़े पैमाने पर विकास किया है।

रिटेल में वृद्धि

खुदरा क्षेत्र पर अपनी वार्षिक रिपोर्ट में रिलायंस



इंडस्ट्रीज ने कहा कि निकट अवधि की मांग व्यापक आर्थिक स्थितियों के प्रति संवेदनशील रह सकती है लेकिन रिटेल क्षेत्र के लिए मध्यम अवधि इसके सकारात्मक रहने की उम्मीद है।

कंपनी ने अपने परिदृश्य में कहा, 'रिलायंस रिटेल को उम्मीद है कि वह विस्तार, परिचालन दक्षता और ग्राहक-केंद्रित नवाचार पर ध्यान केंद्रित करना जारी रखेगी, साथ ही विवेकपूर्ण निवेश और अनुशासित जोखिम प्रबंधन के साथ स्टोर और डिजिटल प्लेटफॉर्म पर अपने एकीकृत पाठिस्थितिकी तंत्र को मजबूत करेगी।' रिलायंस इंडस्ट्रीज की सहायक कंपनी रिलायंस कंज्यूमर प्रोडक्ट्स (आरसीपीएल) एफएमसीजी कारोबार के लिए 2030 तक आय में कई गुना वृद्धि हासिल करने पर ध्यान केंद्रित करना जारी रखेगी और उसकी आकांक्षा अग्रणी वैश्विक ब्रांडेड उपभोक्ता उत्पाद कंपनियों में से एक बनने की है। इसके पेय ब्रांड कैम्पा ने वित्त वर्ष 2025-26 में 4,700 करोड़ रुपये से अधिक की सकल बिक्री हासिल की।

कंपनी ने अपनी वार्षिक रिपोर्ट में कहा कि मार्च 2026 में यह भारत का चौथा सबसे बड़ा कार्बोनेटेड शीतल पेय ब्रांड बन गया और प्रमुख बाजारों में दो अंक में बाजार हिस्सेदारी हासिल की।

अपनी विलय और अधिग्रहण रणनीतियों के बारे में कंपनी ने कहा, 'आरसीपीएल लक्षित रणनीतिक सझेदारी और अधिग्रहणों के साथ-साथ मौजूदा कारोबार का विस्तार करने पर ध्यान देगी। वैश्विक विस्तार कंपनी के लिए एक रणनीतिक प्राथमिकता बनी हुई है।'

प्लास्टिक बैंक नोट की तैयारी

पृष्ठ 1 का शेष

साल 2012 में तत्कालीन सरकार ने कहा था कि प्लास्टिक नोटों को जारी करने का प्राथमिक उद्देश्य उनकी आयु बढ़ाना है न कि नकली नोटों से निपटना। लेकिन तकनीकी चुनौतियों के कारण इस परियोजना को रोक दिया गया था। पिछले एक दशक में हालात बदल गए हैं। सूत्रों के अनुसार तकनीक अब कोई चुनौती नहीं रही और ऐसे समाधान खोज लिए गए हैं जिससे स्वचालित टेलर मशीनें ऐसे नोटों की पहचान कर सकती हैं। दुनिया में लगभग 60 देश ऐसे हैं जिन्होंने पॉलिमर नोटों का उपयोग शुरू कर दिया है। ऑस्ट्रेलिया ने सबसे पहले 1988 में पॉलिमर नोट जारी किया था। इसके बाद सिंगापुर, इंडोनेशिया, थाईलैंड और मलेशिया भी इसी तरह के नोट लेकर आए।

नीट परीक्षा: वायुसेना की मदद लेने पर विचार

सरकार 21 जून को होने वाली नीट-यूजी की पुनर्परीक्षा को पूरी तरह सुरक्षित और त्रुटिरहित ढंग से आयोजित करने के लिए प्रश्नपत्रों को एक स्थान से दूसरे स्थान पर ले जाने के वास्ते भारतीय वायु सेना की सहायता लेने की संभावना पर विचार कर रही है। आधिकारिक सूत्रों ने गुरुवार को यह जानकारी दी।

रक्षा मंत्री राजनाथ सिंह की अध्यक्षता में हुई उच्च स्तरीय बैठक में इस विकल्प पर विचार-विमर्श किया गया। बैठक में शिक्षा मंत्री धर्मेंद्र प्रधान और संचार मंत्री ज्योतिरादित्य सिंधिया भी मौजूद थे। सूत्रों के अनुसार मंत्रियों और वरिष्ठ अधिकारियों ने इस बात पर चर्चा की कि क्या राष्ट्रीय पात्रता सह प्रवेश परीक्षा-स्नातक (नीट-यूजी) प्रश्नपत्रों को एक स्थान से दूसरे स्थान पर ले जाने के लिए वायु सेना के विमानों का इस्तेमाल किया जा सकता है।

Continued from previous page

2) Allotment to Non-Institutional Investors (More than 2 lots and up to ₹ 10,00,000) (After Rejections):

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹ 343/- or above per Equity Share was finalized in consultation with NSE. The category has been subscribed to the extent of 80.67 times i.e. for 2,39,74,800 Equity Shares (after rejection). The total number of Equity Shares Allotted in this category is 2,97,200 Equity Shares to 247 successful applicants. The details of the Basis of Allotment of the said category are as under:

| No. of Shares applied for (Category wise) | Number of applications received | % to total | Total No. of Shares applied in each category | % to total | No of equity shares | Ratio of allottees to applicants | Total No. of shares allocated/allotted | |
|---|---------------------------------|---------------|--|---------------|---------------------|----------------------------------|--|-----|
| 1200 | 16,550 | 89.67 | 1,98,60,000 | 82.83 | 2,66,507.37 | 222:16,550 | 2,66,400 | |
| 1600 | 727 | 3.93 | 11,63,200 | 4.85 | 11,707.00 | 9:727 | 10,800 | |
| 2000 | 283 | 1.53 | 5,66,000 | 2.36 | 4,557.20 | 4:283 | 4,800 | |
| 2400 | 308 | 1.66 | 7,39,200 | 3.08 | 4,959.77 | 4:308 | 4,800 | |
| 2800 | 588 | 3.18 | 16,46,400 | 6.86 | 9,468.66 | 8:588 | 9,600 | |
| 2 out of 25 Successful Allottees from Serial no 2-5 will get Additional 1 lot of 400 shares | | | | | | | 2:25 | 800 |
| TOTAL | 18,456 | 100.00 | 2,39,74,800 | 100.00 | 2,97,200 | | 2,97,200 | |

3) Allotment to Non-Institutional Investors (More than ₹ 10,00,000)

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹ 343/- or above per Equity Share was finalized in consultation with NSE. The category has been subscribed to the extent of 178.11 times i.e. for 10,58,66,000 Equity Shares (after rejection). The total number of Equity Shares Allotted in this category is 5,94,400 Equity to 495 successful applicants. The details of the Basis of Allotment of the said category are as under:

| No. of Shares applied for (Category wise) | Number of applications received | % to total | Total No. of Shares applied in each category | % to total | Proportionate shares available | Ratio of allottees to applicants | Total No. of shares allocated/allotted | |
|--|---------------------------------|------------|--|------------|--------------------------------|----------------------------------|--|------|
| 3,200 | 29,597 | 95.05 | 9,47,10,400 | 89.46 | 5,65,019.81 | 471:29597 | 5,65,200 | |
| 3,600 | 498 | 1.59 | 17,92,800 | 1.69 | 9,507.04 | 8:498 | 9,600 | |
| 4,000 | 273 | 0.87 | 10,92,000 | 1.03 | 5,211.69 | 4:273 | 4,800 | |
| 4,400 | 126 | 0.40 | 5,54,400 | 0.52 | 2,405.40 | 1:63 | 2,400 | |
| 4,800 | 62 | 0.19 | 2,97,600 | 0.28 | 1,183.61 | 1:62 | 1,200 | |
| 5,200 | 85 | 0.27 | 4,42,000 | 0.41 | 1,622.69 | 1:85 | 1,200 | |
| 5,600 | 55 | 0.17 | 3,08,000 | 0.29 | 1,049.97 | 1:55 | 1,200 | |
| 6,000 | 55 | 0.17 | 3,30,000 | 0.31 | 1,049.97 | 1:55 | 1,200 | |
| 6,400 | 81 | 0.26 | 5,18,400 | 0.48 | 1,546.33 | 1:81 | 1,200 | |
| 7,200 | 38 | 0.12 | 2,73,600 | 0.25 | 725.44 | 1:38 | 1,200 | |
| 11,200 | 4 | 0.01 | 44,800 | 0.04 | 76.36 | 0:0 | - | |
| 15,200 | 1 | 0.00 | 15,200 | 0.01 | 19.09 | 0:0 | - | |
| 20,400 | 1 | 0.00 | 20,400 | 0.01 | 19.09 | 0:0 | - | |
| 29,200 | 4 | 0.01 | 1,16,800 | 0.11 | 76.36 | 0:0 | - | |
| 54,000 | 1 | 0.00 | 54,000 | 0.05 | 19.09 | 0:0 | - | |
| 1,46,000 | 1 | 0.00 | 1,46,000 | 0.13 | 19.09 | 0:0 | - | |
| 4 out of 266 un-successful Allottees from Serial no 10 & 12 to 73 will get Additional 1 lot of 1200 shares | | | | | | | 4:266 | 4800 |
| 1 out of 495 successful Allottees will get Additional 1 lot of 400 shares | | | | | | | 1:495 | 400 |

INVESTORS, PLEASE NOTE

The details of the allotment made has been hosted on the website of the Registrar to the Issue, Purva Sharegistry (India) Private Limited

TRACK RECORD OF BOOK RUNNING LEAD MANAGER: The BRLMs associated with the Issue have handled 79 Public Issues in the past three years, out of which 8 issues were closed below the Issue Price on listing date:


| Name of BRLM | Total Issue | | Issue closed below IPO Price on listing date |
|--|-------------|-----------|--|
| | Mainboard | SME | |
| Hem Securities Limited | 2 | 62 | 4 (SME) |
| Share India Capital Services Private Limited | - | 14 | 4 |
| Common* | - | 1 | - |
| Total | 2 | 77 | 8 |

* Issue in which both BRLMs were involved.

All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole Bidder Serial number of the ASBA form, number of Equity Shares bid for, Bidder DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and copy of the Acknowledgment Slip received from the Designated Intermediary and payment details at the address given below:

| | |
|--|---|
| | Purva Sharegistry (India) Private Limited Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011 Tel. No.: 91 22 41343255/41343271 Email: newissue@purvashare.com Website: www.purvashare.com Contact Person: Deepali Gaonkar SEBI Registration No.: INR000001112 |
| | On behalf of Board of Directors Q-Line Biotech Limited Sd/- Akhand Pratap Singh Company Secretary and Compliance Officer |
| | THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF Q-LINE BIOTECH LIMITED |
| | Disclaimer: Q-Line Biotech Limited has filed the Prospectus with the RoC on May 26, 2026 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of the BRLMs, Hem Securities Limited and Share India Capital Services Private Limited at www.hemsecurities.com and www.shareindia.com and the Company at: www.qlinebiotech.com and shall also be available on the website of the NSE and SEBI. Investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 20 of the Prospectus. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public Issuing in the United States. |
| | Place: Lucknow Date: May 27, 2026 |

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



[Please scan this QR Code to view the Prospectus]

Q-LINE BIOTECH LIMITED

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE")

Our Company was originally incorporated as "POCT Services Private Limited" on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to "Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to "Q-Line Biotech Limited", and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled "History and Corporate Structure" beginning on page 152 of the Prospectus.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012
Tel.: +91 522-2435570, E-mail: compliance@qlinebiotech.com ; Website: www.qlinebiotech.com
CIN: U74120UP2010PLC042528 ; Contact Person: Akhand Pratap Singh, Company Secretary & Compliance Officer

OUR PROMOTERS: SAURABH GARG, AMITA GARG, AYUSH GARG, AJAY KUMAR MAHANTY AND ABHAY AGRAWAL

Our Company has filed the Prospectus dated May 26, 2026 with ROC and thereafter with SEBI and the stock exchange and Equity Shares are proposed to be listed on SME Platform of NSE (NSE Emerge) on May 29, 2026.

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE (NSE EMERGE)."

BRIEF DESCRIPTION OF THE BUSINESS OF THE COMPANY

We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of our Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnosics, Molecular Diagnostics and Others (POC Devices & Rapids).

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF UPTO 62,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF Q-LINE BIOTECH LIMITED ("OUR COMPANY" OR "QLBL" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹333 PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ 21,448.48 LAKHS ("PUBLIC ISSUE") OUT OF WHICH 3,13,200 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE FOR CASH, AGGREGATING ₹ 1,074.28 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 59,40,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ 20,374.20 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.81 % AND 25.46 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS RS. 10/- AND ISSUE PRICE IS RS. 343/- EACH. THE ISSUE PRICE IS 34.30 TIMES OF THE FACE VALUE OF THE EQUITY SHARE
ANCHOR INVESTOR ISSUE PRICE: RS. 343/- PER EQUITY SHARE.
THE ISSUE PRICE IS 34.30 TIMES OF THE FACE VALUE

BID/ ISSUE PERIOD

ANCHOR INVESTOR BIDDING DATE: WEDNESDAY, MAY 20, 2026

BID/ ISSUE OPENED ON: THURSDAY, MAY 21, 2026

BID/ ISSUE CLOSED ON: MONDAY, MAY 25, 2026

RISKS TO INVESTORS:

- Any disruption, stoppage, slowdown or shutdown in our manufacturing facilities or process or research and development activities could adversely affect our business, financial condition, cash flows and results of operations.
- Any delay, interruption or reduction in the supply of our raw materials, trade goods from our suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of our products and have an adverse effect on our business, financial condition, cash flows and results of operations.
- Our business is dependent on the sale of our products through distributors which also include our group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of our products and could negatively impact our business, results of operations, financial conditions and cash flows.
- We are dependent on certain key suppliers to procure a significant portion of our Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in our operations, which could have an adverse effect on our business, financial condition, results of operations and cash flows.
- We are required to obtain, maintain or renew our statutory and regulatory approvals, licenses, and registrations to operate our business.
- For manufacturing of our machines and reagents, we are dependent on the agreement with the European companies, any failure to renew the agreement or entering into the agreement on the terms which are not favourable for us may impact our business operations, financial condition and cash flows.
- Our erstwhile associate company i.e. POCT Science House Private Limited and our promoters namely Saurabh Garg and Amita Garg have been subject to search and seizure operations by the Income-tax Department and any adverse outcome of these proceedings may adversely affect our financial condition.
- Our operations are concentrated in North India, and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.
- Our Company requires a significant amount of working capital for continuing growth. Our inability to meet our working capital requirements may adversely affect our results of operations.
- We are subject to risks arising from exchange rate fluctuations.
- The BRLMs associated with the Issue have handled 79 Public Issues in the past three years, out of which 8 issues were closed below the Issue Price on listing date:

| Name of BRLM | Total Issue | | Issue closed below IPO Price on listing date |
|--|-------------|-----------|--|
| | Mainboard | SME | |
| Hem Securities Limited | 2 | 62 | 4 (SME) |
| Share India Capital Services Private Limited | - | 14 | 4 |
| Common* | - | 1 | - |
| Total | 2 | 77 | 8 |

*Issue in which both BRLMs were involved.

- Average cost of acquisition of Equity Shares held by the Promoters is

| Sr. No. | Name of Promoter | No. of Shares held | Average Cost of Acquisition (in ₹) |
|---------|--------------------|--------------------|------------------------------------|
| 1. | Saurabh Garg | 1,01,91,000 | 0.04 |
| 2. | Amita Garg | 39,37,480 | 0.00 |
| 3. | Ayush Garg | 31,500 | 0.00 |
| 4. | Ajay Kumar Mahanty | 7,50,000 | 18.34 |
| 5. | Abhay Agrawal | 7,56,010 | 0.00 |

- The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end (₹343) of the Price Band is 11.98
- Weighted Average Return on Net worth for Fiscals 2025, 2024 and 2023 is 23.17%.
- The Weighted average cost of acquisition of all Equity Shares transacted in the last one year, 18 months and three years from the date of Prospectus is as given below:

| Period | Weighted Average Cost of Acquisition (in Rs.) | Cap Price (₹343) is 'X' times the Weighted Average Cost of Acquisition | Range of acquisition price: Lowest Price – Highest Price (in Rs.) |
|---|---|--|---|
| Last one year, Last 18 Months, three years preceding the date of the Prospectus | 17.88 | 19.18 | 0-343 |

- The Weighted average cost of acquisition compared to Floor Price and Cap Price.

| Types of transactions | Weighted average cost of acquisition (₹ per Equity Shares of face value of Rs. 10/-) | Floor price (i.e. ₹ 326) | Cap price (i.e. ₹ 343) |
|---|--|--------------------------|------------------------|
| Weighted average cost of acquisition of primary / new Issue | NA^^ | NA^ | NA^ |
| Weighted average cost of acquisition for secondary sale / acquisition | NA^^ | NA^^ | NA^^ |
| Weighted average cost of acquisition of primary issuances/ secondary transactions | 17.89 | 18.22 | 19.17 |

Note:
^There were no primary/ new issue of shares (equity/ convertible securities) in last 18 months from the date of the Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days ("Primary Issue").
^^There were no secondary transactions in last 18 months from the date of the Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transaction").

PROPOSED LISTING: MAY 29, 2026*

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), 40% of the Anchor Investor Portion shall be reserved for, (i) 33.33% shall be available for allocation to domestic Mutual Funds, and (ii) 6.67% for life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in (ii) above, the allocation may be made to domestic Mutual Funds in accordance with the SEBI ICDR Regulations. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (1/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than 2 lots and upto such lots equivalent to not more than ₹ 10.00 Lakhs and 2/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than ₹ 10.00 Lakhs and the unsubscribed portion in either of the sub categories, could be allocated to applicants in the other sub-category of NIBs) and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Investors using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 341 of the Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of this Issue, the designated Stock Exchange will be the National Stock Exchange of India Limited. The trading is proposed to be commenced on May 29, 2026 *
*Subject to the receipt of listing and trading approval from the NSE ("NSE EMERGE").

SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on Wednesday, May 20, 2026. The Company received 18 Anchor Investors applications for 20,43,600 Equity Shares. The Anchor Investor Allocation price was finalized at ₹343/- per Equity Share. A total of 17,81,200 Equity Shares were allotted under the Anchor Investors portion aggregating to ₹ 61,09,51,600.00

The Issue (excluding Anchor Investors Portion) received 2,36,894 Applications for 42,80,91,600 Equity Shares (after considering invalid bids, Other than RC10 Transaction declined by Investors, RC10 Mandate not accepted by Investors and Withdrawal/ Cancelled Bids reported by SCSB and rejections) resulting 95.73 times subscription (including reserved portion of market maker and excluding anchor investor portion). The details of the Applications received in the Issue from various categories are as under (before rejections):

Detail of the Applications Received (excluding Anchor Investors Portion):

| Sr. No. | Category | Number of Applications | No. of Equity Shares applied | Equity Shares Reserved as per Prospectus | No. of times Subscribed | Amount (Rs.) |
|---------|--|------------------------|------------------------------|--|-------------------------|--------------------------|
| 1. | Individual Investors | 1,86,599 | 14,92,79,200 | 20,79,200 | 71.80 | 51,19,89,82,000 |
| 2. | Non-institutional Investors (More than 2 lots and up to ₹10 lakhs) | 18,802 | 2,44,19,600 | 2,97,200 | 82.17 | 8,37,28,52,000 |
| 3. | Non-institutional Investors (above ₹10 lakhs) | 31,365 | 10,70,06,400 | 5,94,400 | 180.02 | 36,70,29,09,200 |
| 4. | Qualified Institutional Bidders (excluding Anchors Investors) | 127 | 14,70,73,200 | 11,88,000 | 123.80 | 50,44,61,07,600 |
| 5. | Market Maker | 1 | 3,13,200 | 3,13,200 | 1.00 | 10,74,27,600 |
| | Total | 2,36,894 | 42,80,91,600 | 44,72,000 | 95.73 | 1,46,82,82,78,400 |

Final Demand:

A summary of the final demand as per NSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

| Sr. No. | Bid Price | No. of Equity Shares | % to Total | Cumulative Share Total | Cumulative % of Total |
|---------|-----------|----------------------|------------|------------------------|-----------------------|
| 1 | 326 | 3,23,200 | 0.07% | 3,23,200.00 | 0.07% |
| 2 | 327 | 22,000 | 0.00% | 3,45,200.00 | 0.08% |
| 3 | 328 | 4,800 | 0.00% | 3,50,000.00 | 0.08% |
| 4 | 329 | 6,800 | 0.00% | 3,56,800.00 | 0.08% |
| 5 | 330 | 48,400 | 0.01% | 4,05,200.00 | 0.09% |

| | | | | | |
|----|--------------|---------------------|----------------|-----------------|---------|
| 6 | 331 | 1,600 | 0.00% | 4,06,800.00 | 0.09% |
| 7 | 332 | 4,000 | 0.00% | 4,10,800.00 | 0.09% |
| 8 | 333 | 17,600 | 0.00% | 4,28,400.00 | 0.10% |
| 9 | 334 | 8,400 | 0.00% | 4,36,800.00 | 0.10% |
| 10 | 335 | 42,400 | 0.01% | 4,79,200.00 | 0.11% |
| 11 | 336 | 7,200 | 0.00% | 4,86,400.00 | 0.11% |
| 12 | 337 | 800 | 0.00% | 4,87,200.00 | 0.11% |
| 13 | 338 | 10,000 | 0.00% | 4,97,200.00 | 0.11% |
| 14 | 339 | 10,800 | 0.00% | 5,08,000.00 | 0.11% |
| 15 | 340 | 48,800 | 0.01% | 5,56,800.00 | 0.12% |
| 16 | 341 | 84,800 | 0.02% | 6,41,600.00 | 0.14% |
| 17 | 342 | 1,75,200 | 0.04% | 8,16,800.00 | 0.18% |
| 18 | 343 | 44,75,67,200 | 99.82% | 44,83,84,000.00 | 100.00% |
| | Total | 44,83,84,000 | 100.00% | | |

The Basis of Allotment was finalized in consultation with the designated Stock Exchange, being National Stock Exchange of India Limited ("NSE EMERGE") on May 26, 2026.

- Allotment to Individual Investors (After Rejections):

The Basis of Allotment to the Individual Investors, who have Bid at or above the Issue Price of ₹ 343/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 70.27 times i.e. for 14,61,12,800 Equity Shares. The total number of Equity Shares Allotted in this category is 20,79,200 Equity to 2,599 successful applicants. The details of the Basis of Allotment of the said category are as under:

| No. of Shares Applied for (Category wise) | No. of Applications Received | % of Total | Total No. of Shares Applied | % to Total | No. of Equity Shares Allotted per Applicant | Ratio | Total No. of shares allocated/ allotted |
|---|------------------------------|------------|-----------------------------|------------|---|-------------|---|
| 800 | 182641 | 100.00 | 14,61,12,800 | 100.00 | 800 | 2599:182641 | 20,79,200 |

Continued on next page

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



[Please scan this QR Code to view the Prospectus]

Q-LINE BIOTECH LIMITED

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE")

Our Company was originally incorporated as "POCT Services Private Limited" on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to "Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to "Q-Line Biotech Limited", and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled "History and Corporate Structure" beginning on page 152 of the Prospectus.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012
Tel.: +91 522-2435570, E-mail: compliance@qlinebiotech.com ; Website: www.qlinebiotech.com
CIN: U74120UP2010PLC042528 ; Contact Person: Akhand Pratap Singh, Company Secretary & Compliance Officer

OUR PROMOTERS: SAURABH GARG, AMITA GARG, AYUSH GARG, AJAY KUMAR MAHANTY AND ABHAY AGRAWAL

Our Company has filed the Prospectus dated May 26, 2026 with ROC and thereafter with SEBI and the stock exchange and Equity Shares are proposed to be listed on SME Platform of NSE (NSE Emerge) on May 29, 2026.

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE (NSE EMERGE)."

BRIEF DESCRIPTION OF THE BUSINESS OF THE COMPANY

We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of our Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFER OF UPTO 62,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF Q-LINE BIOTECH LIMITED ("OUR COMPANY" OR "QLBL" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹333 PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ 21,448.48 LAKHS ("PUBLIC ISSUE") OUT OF WHICH 3,13,200 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE FOR CASH, AGGREGATING ₹ 1,074.28 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 59,40,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ 343 PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ 20,374.20 LAKHS IS HEREIN REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.81 % AND 25.46 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS RS. 10/- AND ISSUE PRICE IS RS. 343/- EACH. THE ISSUE PRICE IS 34.30 TIMES OF THE FACE VALUE OF THE EQUITY SHARE
ANCHOR INVESTOR ISSUE PRICE: RS. 343/- PER EQUITY SHARE.
THE ISSUE PRICE IS 34.30 TIMES OF THE FACE VALUE

BID/ ISSUE PERIOD

ANCHOR INVESTOR BIDDING DATE: WEDNESDAY, MAY 20, 2026

BID/ ISSUE OPENED ON: THURSDAY, MAY 21, 2026

BID/ ISSUE CLOSED ON: MONDAY, MAY 25, 2026

RISKS TO INVESTORS:

- Any disruption, stoppage, slowdown or shutdown in our manufacturing facilities or process or research and development activities could adversely affect our business, financial condition, cash flows and results of operations.
- Any delay, interruption or reduction in the supply of our raw materials, trade goods from our suppliers and manufacturers both domestic and imported, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of our products and have an adverse effect on our business, financial condition, cash flows and results of operations.
- Our business is dependent on the sale of our products through distributors which also include our group entity POCT services. The loss of any of these distributors or third parties for any reason may adversely affect the marketing and distribution of our products and could negatively impact our business, results of operations, financial conditions and cash flows.
- We are dependent on certain key suppliers to procure a significant portion of our Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in our operations, which could have an adverse effect on our business, financial condition, results of operations and cash flows.
- We are required to obtain, maintain or renew our statutory and regulatory approvals, licenses, and registrations to operate our business.
- For manufacturing of our machines and reagents, we are dependent on the agreement with the European companies, any failure to renew the agreement or entering into the agreement on the terms which are not favourable for us may impact our business operations, financial condition and cash flows.
- Our erstwhile associate company i.e. POCT Science House Private Limited and our promoters namely Saurabh Garg and Amita Garg have been subject to search and seizure operations by the Income-tax Department and any adverse outcome of these proceedings may adversely affect our financial condition.
- Our operations are concentrated in North India, and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.
- Our Company requires a significant amount of working capital for continuing growth. Our inability to meet our working capital requirements may adversely affect our results of operations.
- We are subject to risks arising from exchange rate fluctuations.
- The BRLMs associated with the Issue have handled 79 Public Issues in the past three years, out of which 8 issues were closed below the Issue Price on listing date:

| Name of BRLM | Total Issue | | Issue closed below IPO Price on listing date |
|--|-------------|-----------|--|
| | Mainboard | SME | |
| Hem Securities Limited | 2 | 62 | 4 (SME) |
| Share India Capital Services Private Limited | - | 14 | 4 |
| Common* | - | 1 | - |
| Total | 2 | 77 | 8 |

*Issue in which both BRLMs were involved.

- Average cost of acquisition of Equity Shares held by the Promoters is

| Sr. No. | Name of Promoter | No. of Shares held | Average Cost of Acquisition (in ₹) |
|---------|--------------------|--------------------|------------------------------------|
| 1. | Saurabh Garg | 1,01,91,000 | 0.04 |
| 2. | Amita Garg | 39,37,480 | 0.00 |
| 3. | Ayush Garg | 31,500 | 0.00 |
| 4. | Ajay Kumar Mahanty | 7,50,000 | 18.34 |
| 5. | Abhay Agrawal | 7,56,010 | 0.00 |

- The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end (₹343) of the Price Band is 11.98
- Weighted Average Return on Net worth for Fiscals 2025, 2024 and 2023 is 23.17%.
- The Weighted average cost of acquisition of all Equity Shares transacted in the last one year, 18 months and three years from the date of Prospectus is as given below:

| Period | Weighted Average Cost of Acquisition (in Rs.) | Cap Price (₹343) times the Weighted Average Cost of Acquisition | Range of acquisition price: Lowest Price – Highest Price (in Rs.) |
|---|---|---|---|
| Last one year, Last 18 Months, three years preceding the date of the Prospectus | 17.88 | 19.18 | 0-343 |

- The Weighted average cost of acquisition compared to Floor Price and Cap Price.

| Types of transactions | Weighted average cost of acquisition (₹ per Equity Shares of face value of Rs. 10/-) | Floor price (i.e. ₹ 326) | Cap price (i.e. ₹ 343) |
|---|--|--------------------------|------------------------|
| Weighted average cost of acquisition of primary / new Issue | NA^ | NA^ | NA^ |
| Weighted average cost of acquisition for secondary sale / acquisition | NA^^ | NA^^ | NA^^ |
| Weighted average cost of acquisition of primary issuances/ secondary transactions | 17.89 | 18.22 | 19.17 |

Note:
^There were no primary/ new issue of shares (equity/ convertible securities) in last 18 months from the date of the Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of 30 days ("Primary Issue").
^^There were no secondary transactions in last 18 months from the date of the Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transaction").

PROPOSED LISTING: MAY 29, 2026*

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), 40% of the Anchor Investor Portion shall be reserved for, (i) 33.33% shall be available for allocation to domestic Mutual Funds, and (ii) 6.67% for life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price. In the event of under-subscription in (ii) above, the allocation may be made to domestic Mutual Funds in accordance with the SEBI ICDR Regulations. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (1/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than 2 lots and upto such lots equivalent to not more than ₹ 10.00 Lakhs and 2/3rd of the portion available to NIBs shall be reserved for applicants with an application size of more than ₹ 10.00 Lakhs and the unsubscribed portion in either of the sub categories, could be allocated to applicants in the other sub-category of NIBs) and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Investors using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 341 of the Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of this Issue, the designated Stock Exchange will be the National Stock Exchange of India Limited. The trading is proposed to be commenced on May 29, 2026 *
*Subject to the receipt of listing and trading approval from the NSE ("NSE EMERGE").

SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on Wednesday, May 20, 2026. The Company received 18 Anchor Investors applications for 20,43,600 Equity Shares. The Anchor Investor Allocation price was finalized at ₹343/- per Equity Share. A total of 17,81,200 Equity Shares were allotted under the Anchor Investors portion aggregating to ₹ 61,09,51,600.00

The Issue (excluding Anchor Investors Portion) received 2,36,894 Applications for 42,80,91,600 Equity Shares (after considering invalid bids, Other than RC10 Transaction declined by Investors, RC10 Mandate not accepted by Investors and Withdrawal/ Cancelled Bids reported by SCSB and rejections) resulting 95.73 times subscription (including reserved portion of market maker and excluding anchor investor portion). The details of the Applications received in the Issue from various categories are as under (before rejections):

Detail of the Applications Received (excluding Anchor Investors Portion):

| Sr. No. | Category | Number of Applications | No. of Equity Shares applied | Equity Shares Reserved as per Prospectus | No. of times Subscribed | Amount (Rs.) |
|---------|--|------------------------|------------------------------|--|-------------------------|--------------------------|
| 1. | Individual Investors | 1,86,599 | 14,92,79,200 | 20,79,200 | 71.80 | 51,19,89,82,000 |
| 2. | Non-institutional Investors (More than 2 lots and up to ₹10 lakhs) | 18,802 | 2,44,19,600 | 2,97,200 | 82.17 | 8,37,28,52,000 |
| 3. | Non-institutional Investors (above ₹10 lakhs) | 31,365 | 10,70,06,400 | 5,94,400 | 180.02 | 36,70,29,09,200 |
| 4. | Qualified Institutional Bidders (excluding Anchors Investors) | 127 | 14,70,73,200 | 11,88,000 | 123.80 | 50,44,61,07,600 |
| 5. | Market Maker | 1 | 3,13,200 | 3,13,200 | 1.00 | 10,74,27,600 |
| | Total | 2,36,894 | 42,80,91,600 | 44,72,000 | 95.73 | 1,46,82,82,78,400 |

Final Demand:
A summary of the final demand as per NSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

| Sr. No. | Bid Price | No. of Equity Shares | % to Total | Cumulative Share Total | Cumulative % of Total |
|---------|-----------|----------------------|------------|------------------------|-----------------------|
| 1 | 326 | 3,23,200 | 0.07% | 3,23,200.00 | 0.07% |
| 2 | 327 | 22,000 | 0.00% | 3,45,200.00 | 0.08% |
| 3 | 328 | 4,800 | 0.00% | 3,50,000.00 | 0.08% |
| 4 | 329 | 6,800 | 0.00% | 3,56,800.00 | 0.08% |
| 5 | 330 | 48,400 | 0.01% | 4,05,200.00 | 0.09% |

| | | | | | |
|----|--------------|---------------------|----------------|-----------------|---------|
| 6 | 331 | 1,600 | 0.00% | 4,06,800.00 | 0.09% |
| 7 | 332 | 4,000 | 0.00% | 4,10,800.00 | 0.09% |
| 8 | 333 | 17,600 | 0.00% | 4,28,400.00 | 0.10% |
| 9 | 334 | 8,400 | 0.00% | 4,36,800.00 | 0.10% |
| 10 | 335 | 42,400 | 0.01% | 4,79,200.00 | 0.11% |
| 11 | 336 | 7,200 | 0.00% | 4,86,400.00 | 0.11% |
| 12 | 337 | 800 | 0.00% | 4,87,200.00 | 0.11% |
| 13 | 338 | 10,000 | 0.00% | 4,97,200.00 | 0.11% |
| 14 | 339 | 10,800 | 0.00% | 5,08,000.00 | 0.11% |
| 15 | 340 | 48,800 | 0.01% | 5,56,800.00 | 0.12% |
| 16 | 341 | 84,800 | 0.02% | 6,41,600.00 | 0.14% |
| 17 | 342 | 1,75,200 | 0.04% | 8,16,800.00 | 0.18% |
| 18 | 343 | 44,75,67,200 | 99.82% | 44,83,84,000.00 | 100.00% |
| | Total | 44,83,84,000 | 100.00% | | |

The Basis of Allotment was finalized in consultation with the designated Stock Exchange, being National Stock Exchange of India Limited ("NSE EMERGE") on May 26, 2026.

- Allotment to Individual Investors (After Rejections):

The Basis of Allotment to the Individual Investors, who have Bid at or above the Issue Price of ₹ 343/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 70.27 times i.e. for 14,61,12,800 Equity Shares. The total number of Equity Shares Allotted in this category is 20,79,200 Equity to 2,599 successful applicants. The details of the Basis of Allotment of the said category are as under:

| No. of Shares Applied for (Category wise) | No. of Applications Received | % of Total | Total No. of Shares Applied | % to Total | No. of Equity Shares Allotted per Applicant | Ratio | Total No. of shares allocated/ allotted |
|---|------------------------------|------------|-----------------------------|------------|---|-------------|---|
| 800 | 182641 | 100.00 | 14,61,12,800 | 100.00 | 800 | 2599:182641 | 20,79,200 |

Continued on next page

Continued from previous page

2) Allotment to Non-Institutional Investors (More than 2 lots and up to ₹ 10,00,000) (After Rejections):

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹ 343/- or above per Equity Share was finalized in consultation with NSE. The category has been subscribed to the extent of 80.67 times i.e. for 2,39,74,800 Equity Shares (after rejection). The total number of Equity Shares Allotted in this category is 2,97,200 Equity Shares to 247 successful applicants. The details of the Basis of Allotment of the said category are as under:

| No. of Shares applied for (Category wise) | Number of applications received | % to total | Total No. of Shares applied in each category | % to total | No of equity shares | Ratio of allottees to applicants | Total No. of shares allocated/allotted |
|---|---------------------------------|---------------|--|---------------|---------------------|----------------------------------|--|
| 1200 | 16,550 | 89.67 | 1,98,60,000 | 82.83 | 2,66,507.37 | 222:16,550 | 2,66,400 |
| 1600 | 727 | 3.93 | 11,63,200 | 4.85 | 11,707.00 | 9:727 | 10,800 |
| 2000 | 283 | 1.53 | 5,66,000 | 2.36 | 4,557.20 | 4:283 | 4,800 |
| 2400 | 308 | 1.66 | 7,39,200 | 3.08 | 4,959.77 | 4:308 | 4,800 |
| 2800 | 588 | 3.18 | 16,46,400 | 6.86 | 9,468.66 | 8:588 | 9,600 |
| 2 out of 25 Successful Allottees from Serial no 2-5 will get Additional 1 lot of 400 shares | | | | | | 2:25 | 800 |
| TOTAL | 18,456 | 100.00 | 2,39,74,800 | 100.00 | 2,97,200 | | 2,97,200 |

3) Allotment to Non-Institutional Investors (More than ₹ 10,00,000)

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹ 343/- or above per Equity Share was finalized in consultation with NSE. The category has been subscribed to the extent of 178.11 times i.e. for 10,58,66,000 Equity Shares (after rejection). The total number of Equity Shares Allotted in this category is 5,94,400 Equity to 495 successful applicants. The details of the Basis of Allotment of the said category are as under:

| No. of Shares applied for (Category wise) | Number of applications received | % to total | Total No. of Shares applied in each category | % to total | Proportionate shares available | Ratio of allottees to applicants | Total No. of shares allocated/allotted |
|--|---------------------------------|------------|--|------------|--------------------------------|----------------------------------|--|
| 3,200 | 29,597 | 95.05 | 9,47,10,400 | 89.46 | 5,65,019.81 | 471:29,597 | 5,65,200 |
| 3,600 | 498 | 1.59 | 17,92,800 | 1.69 | 9,507.04 | 8:498 | 9,600 |
| 4,000 | 273 | 0.87 | 10,92,000 | 1.03 | 5,211.69 | 4:273 | 4,800 |
| 4,400 | 126 | 0.40 | 5,54,400 | 0.52 | 2,405.40 | 1:126 | 2,400 |
| 4,800 | 62 | 0.19 | 2,97,600 | 0.28 | 1,183.61 | 1:62 | 1,200 |
| 5,200 | 85 | 0.27 | 4,42,000 | 0.41 | 1,622.69 | 1:85 | 1,200 |
| 5,600 | 55 | 0.17 | 3,08,000 | 0.29 | 1,049.97 | 1:55 | 1,200 |
| 6,000 | 55 | 0.17 | 3,30,000 | 0.31 | 1,049.97 | 1:55 | 1,200 |
| 6,400 | 81 | 0.26 | 5,18,400 | 0.48 | 1,546.33 | 1:81 | 1,200 |
| 7,200 | 38 | 0.12 | 2,73,600 | 0.25 | 725.44 | 1:38 | 1,200 |
| 11,200 | 4 | 0.01 | 44,800 | 0.04 | 76.36 | 0:0 | - |
| 15,200 | 1 | 0.00 | 15,200 | 0.01 | 19.09 | 0:0 | - |
| 20,400 | 1 | 0.00 | 20,400 | 0.01 | 19.09 | 0:0 | - |
| 29,200 | 4 | 0.01 | 1,16,800 | 0.11 | 76.36 | 0:0 | - |
| 54,000 | 1 | 0.00 | 54,000 | 0.05 | 19.09 | 0:0 | - |
| 1,46,000 | 1 | 0.00 | 1,46,000 | 0.13 | 19.09 | 0:0 | - |
| 4 out of 266 un-successful Allottees from Serial no 10 & 12 to 73 will get Additional 1 lot of 1200 shares | | | | | | 4:266 | 4800 |
| 1 out of 495 successful Allottees will get Additional 1 lot of 400 shares | | | | | | 1:495 | 400 |

4) Allotment to Market Maker: The Basis of Allotment to Market Maker who have bid at Issue Price of ₹ 343/- per Equity Shares or above, was finalized in consultation with NSE. The category was subscribed by 1.00 times i.e. for 3,13,200 Equity shares the total number of shares allotted in this category is 3,13,200 Equity Shares. The category wise details of the Basis of Allotment are as under:

| No. of Shares Applied for (Category wise) | No. of Applications received | % to total | Total No. of Equity Shares applied in this Category | % of total | No. of Equity Shares allocated/ allotted per Applicant | Ratio | Total No. of shares allocated/allotted |
|---|------------------------------|------------|---|------------|--|-------|--|
| 3,13,200 | 1 | 100.00 | 3,13,200 | 100.00 | 3,13,200 | 1:1 | 3,13,200 |

5) Allotment to QIBs excluding Anchor Investors (After Rejections):

The Basis of Allotment to QIBs, who have bid at Issue Price of ₹ 343/- per Equity Shares or above, was finalized in consultation with NSE. The category was subscribed by 123.80 times i.e. for 14,70,73,200 Equity shares. As per the SEBI Regulations, 5% of Net QIB portion was reserved for mutual funds i.e. 59,200 Equity Shares and other QIBs and unsatisfied demand of Mutual Funds were allotted the remaining available Equity Shares i.e. 11,28,800 Equity Shares on a proportionate basis. The total number of shares allotted in this category is 11,88,000 Equity Shares to 115 successful applicants. The category wise details of the Basis of Allotment are as under:

| Category | FI'S/BANK'S | MF'S | IC'S | NBFC'S | AIF | FPC/FII | Others | Total |
|----------|-------------|--------|-------|----------|----------|----------|----------|-----------|
| QIB | 2,02,000 | 79,600 | 4,400 | 1,53,600 | 3,78,000 | 1,58,800 | 2,11,600 | 11,88,000 |

6) Allotment to Anchor Investors (After Rejections):

The Company in consultation with the BRLM has allocated 17,81,200 Equity Shares to 18 Anchor Investors at the Anchor Investor Issue Price of ₹ 343/- per Equity Shares in accordance with the SEBI (ICDR) Regulations. This represents upto 60% of the QIB Category.

| CATEGORY | FIS/BANKS | MF'S | IC'S | NBFC'S | AIF | FPI/FPC | VC'S | TOTAL |
|----------|-----------|----------|------|--------|-----------|----------|------|-----------|
| ANCHOR | 29,200 | 2,91,600 | - | 29,200 | 12,00,400 | 2,30,800 | - | 17,81,200 |

The Board of Directors of our Company at its meeting held on May 26, 2026 has taken on record the basis of allotment of Equity Shares approved by the designated Stock Exchange, being NSE and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched / mailed for unblocking of funds and transfer to the Public Issue Account on or before May 27, 2026. In case the same is not received within ten days, Investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on May 27, 2026 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from NSE and the trading of the Equity Shares is expected to commence trading on May 29, 2026.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated May 26, 2026 filed with the Registrar of Companies, Uttar Pradesh I ("RoC").

INVESTORS, PLEASE NOTE

The details of the allotment made has been hosted on the website of the Registrar to the Issue, Purva Sharegistry (India) Private Limited

TRACK RECORD OF BOOK RUNNING LEAD MANAGER: The BRLMs associated with the Issue have handled 79 Public Issues in the past three years, out of which 8 issues were closed below the Issue Price on listing date:

| Name of BRLM | Total Issue | | Issue closed below IPO Price on listing date |
|--|-------------|-----------|--|
| | Mainboard | SME | |
| Hem Securities Limited | 2 | 62 | 4 (SME) |
| Share India Capital Services Private Limited | - | 14 | 4 |
| Common* | - | 1 | - |
| Total | 2 | 77 | 8 |

*Issue in which both BRLMs were involved.

All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole Bidder Serial number of the ASBA form, number of Equity Shares bid for, Bidder DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and copy of the Acknowledgment Slip received from the Designated Intermediary and payment details at the address given below:



Purva Sharegistry (India) Private Limited
Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011
Tel. No.: 91 22 41343255/41343271
Email: newissue@purvashare.com
Website: www.purvashare.com
Contact Person: Deepali Gaonkar
SEBI Registration No.: INR000001112

On behalf of Board of Directors
Q-Line Biotech Limited
Sd/-
Akhand Pratap Singh
Company Secretary and Compliance Officer

Place: Lucknow
Date: May 27, 2026

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF Q-LINE BIOTECH LIMITED

Disclaimer: Q-Line Biotech Limited has filed the Prospectus with the RoC on May 26, 2026 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of the BRLMs, Hem Securities Limited and Share India Capital Services Private Limited at www.hemsecurities.com and www.shareindia.com and the Company at: www.qlinebiotech.com and shall also be available on the website of the NSE and SEBI. Investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see "Risk Factors" beginning on page 20 of the Prospectus. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such Issues and sales are made. There will be no public Issuing in the United States.

यदि सकारात्मक समाचारों को नजरअंदाज किया गया तो युवा कॉकरोच का अनुसरण करेंगे : उपराष्ट्रपति

कोट्टायम (केरल), (भाषा)। उपराष्ट्रपति सी पी राधाकृष्णन ने कॉकरोच जनता पार्टी (सीजेपी) के परीक्ष संदर्भ में रविवार को कहा कि अगर सकारात्मक गतिविधियों और उपलब्धियों की पर्याप्त रिपोर्टिंग नहीं की गई, तो युवा अंततः कॉकरोच का अनुसरण करेंगे। उन्होंने इस बात पर जोर दिया कि समाज को सही राह दिखाने और जनता का विश्वास मजबूत करने के लिए रचनात्मक पत्रकारिता आवश्यक है। मलयालम दैनिक दीपिका की 140वीं वर्षगांठ के समारोह में मुख्य अतिथि के रूप में राधाकृष्णन ने कहा कि सकारात्मक विकास पर मीडिया में अधिक ध्यान दिया जाना चाहिए, ताकि युवाओं को सही जानकारी और आदर्श मिल सकें। उन्होंने कहा, सकारात्मक गतिविधियों की अच्छी तरह से रिपोर्टिंग की जानी चाहिए। तभी युवाओं को सही जानकारी मिलेगी। अन्यथा, वे रुचि खो देंगे और अंततः कॉकरोच की राह पर चल पड़ेंगे। उपराष्ट्रपति ने कहा कि प्रधानमंत्री नरेन्द्र मोदी के नेतृत्व में भारत आत्मविश्वास

» हम 2047 तक सबसे विकसित राष्ट्र बनना चाहते हैं। समाज के हर वर्ग के योगदान के बिना यह लक्ष्य हासिल नहीं किया जा सकता



रूप से युवाओं के बीच उत्पन्न सोशल मीडिया हलचल का जिक्र करते हुए, उन्होंने सवाल उठाया कि क्या वास्तव में कोई चीज एक ही दिन में इतना ध्यान आकर्षित करने लायक है। उन्होंने कहा, अगर कोई चीज वाकई अच्छी

है, तो लोग एक हफ्ते, 10 दिन या यहां तक कि एक महीने बाद भी उसके महत्व को पहचानते रहेंगे। राधाकृष्णन ने कहा, उनके बारे में कोई नहीं जानता। अचानक, वे हर जगह फैल गए हैं। यह ज्यादा समय तक नहीं चल सकता। उन्होंने साथ ही इस बात पर जोर दिया कि नेक विचार और सकारात्मक संदेश समाज के हर कोने तक पहुंचने चाहिए तथा राष्ट्र निर्माण में योगदान देना चाहिए। भारत के प्रधान न्यायाधीश सूर्यकांत द्वारा अदालत में एक सुनवाई के दौरान की गई कॉकरोच और परजीवी संबंधी टिप्पणी से उत्पन्न विवाद के बाद यह व्यंग्यात्मक मंच सामने आया। बाद में, न्यायमूर्ति सूर्यकांत ने स्पष्ट किया कि फर्जी डिग्रियों के माध्यम से विधि पेश में प्रवेश करने वाले व्यक्तियों को लेकर उनके द्वारा की गई टिप्पणी को गलत तरीके से उद्धृत किया गया। उपराष्ट्रपति ने कहा कि राष्ट्र का विकास किसी एक व्यक्ति, एक पार्टी या एक सरकार का कर्तव्य नहीं है। उन्होंने कहा, यह इस देश के प्रत्येक नागरिक का प्राथमिक कर्तव्य है।

एमबीबीएस पाठ्यक्रम पूरा करने की समयसीमा फिर 10 वर्ष करने का प्रस्ताव, एनएमसी ने मांगी राय

नई दिल्ली, (भाषा)। राष्ट्रीय आयुर्विज्ञान आयोग (एनएमसी) ने स्नातक चिकित्सा शिक्षा विनियम (जीएमईआर), 2023 में संशोधन का प्रस्ताव किया है, जिससे एमबीबीएस छात्रों को अनिवार्य रोटेटरी मेडिकल इंटरशिप सहित पाठ्यक्रम पूरा करने के लिए अधिकतम 10 वर्ष का समय मिले। इस प्रस्ताव के लागू होने से वर्ष 2023 से पहले लागू समयसीमा प्रभावी रूप से बहाल हो जाएगी। आयोग ने अपनी वेबसाइट पर अपलोड किए गए मसौदा संशोधन में हितधारकों और आम जनता से 30 दिनों के भीतर सुझाव और टिप्पणियां आमंत्रित की हैं। प्रस्तावित संशोधनों के अनुसार, प्रथम व्यावसायिक एमबीबीएस परीक्षा उत्तीर्ण करने के लिए छात्रों को अधिकतम चार प्रयास ही मिलेंगे।

टीएमसी की हार के बाद पश्चिम बंगाल में हिंसा की घटनाएं बढ़ीं : अशोक गहलोत

जयपुर, (भाषा)। राजस्थान के पूर्व मुख्यमंत्री अशोक गहलोत ने पश्चिम बंगाल में तुणमूल कांग्रेस (टीएमसी) संसद अंधिषेक बनर्जी पर हमले की खबरों के बाद रविवार को राज्य में कानून-व्यवस्था के बिगड़ने का आरोप लगाया और इसके लिए भाजपा तथा निर्वाचन आयोग को जिम्मेदार ठहराया। बनर्जी पर हमले पर प्रतिक्रिया देते हुए गहलोत ने दावा किया कि चुनावों में टीएमसी की हार के बाद राज्य में हिंसा की घटनाएं बढ़ गई हैं। उन्होंने पत्रकारों से कहा, बनर्जी के बारे में जो आप कह रहे हैं, वह इसलिए सामने आ रहा है क्योंकि वह प्रमुख नेता हैं। लेकिन चुनावों के बाद से पश्चिम बंगाल में व्यापक गुंडागर्दी हो रही है। गहलोत ने आरोप लगाया कि टीएमसी कार्यकर्ताओं के दफ्तरों पर हमले किए जा रहे हैं और उन्हें जबरन खाली



कराया जा रहा है। उन्होंने दावा किया कि इन घटनाओं में भाजपा और आरएसएस से जुड़े लोग शामिल हैं। उन्होंने निर्वाचन आयोग की भी आलोचना की और कहा कि चुनाव के दौरान असामान्य रूप से बड़ी संख्या में सुरक्षा बलों की तैनाती ने प्रक्रिया को प्रभावित किया। गहलोत ने कहा, एक ही राज्य में करीब 2.5 लाख जवानों की तैनाती की गई। यह अभूतपूर्व था।

असम मंत्रिपरिषद का पांच जून को विस्तार होगा : हिमंत



गुवाहाटी, (भाषा)। असम के मुख्यमंत्री हिमंत विश्व शर्मा ने रविवार को कहा कि अगले सप्ताह नए मंत्रियों के शपथ लेने के साथ उनके मंत्रिपरिषद का विस्तार किया जाएगा। शर्मा को लगातार दूसरे कार्यकाल के लिए राज्यपाल लक्ष्मण प्रसाद आचार्य द्वारा 12 मई को

मुख्यमंत्री पद की शपथ दिलाई गई थी। शर्मा के शपथ ग्रहण समारोह में प्रधानमंत्री नरेन्द्र मोदी, कई केंद्रीय मंत्रियों, राष्ट्रीय जनतांत्रिक गठबंधन (राजग)-शासित राज्यों के मुख्यमंत्रियों और अन्य शीर्ष गणमान्य व्यक्ति मौजूद थे। मुख्यमंत्री के साथ चार अन्य मंत्रियों ने भी शपथ ली थी। इनमें भारतीय जनता पार्टी (भाजपा) की अर्जुन निरोग और रामेश्वर तेली, असम गण परिषद के अतुल बोरा और बोडोलैंड पीपुल्स फ्रंट (बीपीएफ) के चरन बोरो शामिल थे। शर्मा ने एक्स पर लिखा, मुझे यह बताते हुए प्रसन्नता हो रही है कि असम सरकार की मंत्रिपरिषद का विस्तार पांच जून, 2026 को किया जाएगा।

नॉर्थ, साउथ ब्लॉक को संग्रहालय में तब्दील करने के लिए विशेषज्ञ समूह का चयन किया गया : शेखावत

नई दिल्ली, (भाषा)। केंद्रीय संस्कृति मंत्री गजेन्द्र सिंह शेखावत ने कहा है कि नॉर्थ ब्लॉक और साउथ ब्लॉक को उनके मूल स्वरूप में बहाल करने का काम शुरू हो गया है तथा इसके बाद इन्हें युगीन भारत राष्ट्रीय संग्रहालय में तब्दील करने की महत्वाकांक्षी परियोजना पर वैश्विक निविदा के जरिए चुने गए एक विशेषज्ञ समूह के साथ काम शुरू किया जाएगा। बुधवार को पीटीआई-वीडियो को दिए एक साक्षात्कार में उन्होंने बताया कि प्रधानमंत्री नरेन्द्र मोदी ने संस्कृति मंत्रालय के सामने वर्ष 2028 तक परियोजना के पहले चरण को पूरा करने का उद्घाटन करने का लक्ष्य रखा है। दुनिया के सबसे बड़े संग्रहालय के रूप में तैयार किए जा रहे इस संग्रहालय में भारत की 5,000 वर्षों से अधिक



पुरानी सभ्यता और संस्कृति की कहानी को आठ विषयगत खंडों के माध्यम से प्रस्तुत किया जाएगा। देश की राजधानी नई दिल्ली के केंद्र में स्थित नॉर्थ ब्लॉक और साउथ ब्लॉक में विकसित होने वाला यह संग्रहालय लगभग 1.5 लाख वर्गमीटर क्षेत्र में फैला होगा। पहले

» दुनिया के सबसे बड़े संग्रहालय के रूप में तैयार किए जा रहे इस संग्रहालय में भारत की 5,000 वर्षों से अधिक पुरानी सभ्यता और संस्कृति की कहानी को आठ विषयगत खंडों के माध्यम से प्रस्तुत किया जाएगा

जहां गृह मंत्रालय, वित्त मंत्रालय और अन्य सरकारी विभागों वाला नॉर्थ ब्लॉक खाली कराया जा चुका है, वहीं कई महत्वपूर्ण मंत्रालयों वाले साउथ ब्लॉक को भी चरणबद्ध तरीके से खाली किया जा रहा है।

पश्चिम बंगाल में कानून-व्यवस्था की बिगड़ती स्थिति चिंताजनक : मुफ्ती



श्रीनगर, (भाषा)। पीपुल्स डेमोक्रेटिक पार्टी (पीडीपी) अध्यक्ष महबूबा मुफ्ती ने रविवार को कहा कि इस महीने की शुरुआत में पश्चिम बंगाल विधानसभा चुनाव में भाजपा की जीत के बाद वहां कानून-व्यवस्था की बिगड़ती स्थिति चिंताजनक है। मुफ्ती ने सोशल मीडिया मंच एक्स पर एक पोस्ट में कहा, पश्चिम बंगाल चुनाव में भाजपा की जीत के बाद से

कानून-व्यवस्था की बिगड़ती स्थिति बेहद चिंताजनक है। जहां पुलिस जैसी निष्पक्ष संस्थाओं का अब इस तरह से दुरुपयोग किया जा रहा है कि वे अंधिषेक बनर्जी जैसे राजनीतिक विरोधियों के खिलाफ जानलेवा हमलों पर आखें मूंद लें। वह विपक्षी तुणमूल कांग्रेस के नेता अंधिषेक बनर्जी पर भीड़ द्वारा किए गए हमले पर प्रतिक्रिया दे रही थीं। जम्मू-कश्मीर के पूर्व मुख्यमंत्री ने कहा कि यह निश्चित रूप से वैसा बदलाव नहीं है जिसके लिए पश्चिम बंगाल के लोगों ने मतदान किया था। उन्होंने कहा, क्या पश्चिम बंगाल के लोगों ने इसी बदलाव के लिए वोट दिया था? बिल्कुल नहीं।